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EFFECT OF NIFEDIPINE ON ANALGESIA 
INDUCED BY GABAa AND GABAB 
RECEPTOR AGONISTS IN RATS 
G. Gebers, L. Allikmets, A. Zharkovsky 
Department of Pharmacology, Tartu University 
Abstract 
In the present study, we found that DHP calcium channel antagonist 
nifedipine exerted an antinociceptive activity following systemic adminis­
tration. In agreement with earlier observations, these data suggest that 
nifedipine might possess a certain analgesic properties. In order to test a 
possibility that GABA-sensitive mechanisms may be involved in the 
antinociceptive effect of nifedipine, series of experiments were carried out 
in which the effects of subanalgesic dose of nifedipine on САВАд agonist 
muscimol- and GABAg agonist baclofen-induced analgesia in the hot-plate 
test in rats were studied. When co-administered with baclofen nifedipine 
significantly potentiated baclofen-induced analgesia. On the other hand, 
co-administration of nifedipine with muscimol did not affect muscimol-
induced analgesia. Data obtained in our study suggest the existence of 
functional interaction between dihydropyridine binding site and GABAg 
receptors. 
Introduction 
Gamma-ami nobutyric, acid (GABA) receptors have been classified into 
САВАд and GABAg subtypes on the basis of their pharmacological and 
anatomical properties [4]. САВАд receptor contains a chloride channel, 
while GABAg receptörOf? thought to modulate potassium and calcium 
ion conductances [9]. GABAergic mechanisms appear to be involved in 
antinociceptive processes. Thus, it has been shown that both САВАд and 
GABAg receptor agonists can induce analgesia in variety of animal test 
systems when administrated either intraperitoneally [14, 16] or centrally 
[17]. 
3 
Current evidence indicates that calcium ion plays an important role 
in the nociception. It is known that the intracerebroventricular or the 
subcutaneous administration of calcium antagonizes analgesia whereas the 
administration of EDTA induces opposite effects [11]. Moreover, the 
analgesic action of opiates is accompanied by their interaction with 
calcium influx into the cells through the voltage-sensitive calcium channels 
[5]. These calcium channels are sensitive to blockade by dihydropyridine 
(DHP) antagonists and to activation by the DHP agonist BAY K8644 [19] 
suggesting that the functional role of central DHP binding sites might be 
to modulate the Ca^+ entry into the cells subsequently modifying the 
Ca^+-dependent cellular functions. Del Pozo and co-workers recently found 
that calcium channel antagonisti produce analgesic effect when adminis­
trated alone as well as enhance antinociceptive actions of morphine in 
rodents [6]. 
In view of the above findings the present study was designed to 
examine the effects of DHP calcium channel antagonist nifedipine on 
analgesia induced by САВАд and GABAg receptor agonists muscimol and 
baclofen. Finally, since it has been shown that some of the pharmacologi­
cal effects of ethanol may be mediated through GABA receptors [1] we 
decided to study also the effects of DHP calcium channel antagonist and 
agonist on ethanol-induced analgesia. 
Materials and method 
Animals. The experiments were carried out on female Wistar rats, 
weighing 220-240 g, kept under standard laboratory conditions, with free 
access to standard laboratory food and tap water, at room temperature of 
approx 22* C, in natural day-night cycle. On the day of testing, subjects 
were transported to a laboratory room, weighed, and assigned randomly 
to receive either vehicle or drug treatment. 
Drugs and drug treatment. Baclofen (CIBA-GEIGY, Switzerland) 
and muscimol (Biochemica Merck, Germany) were dissolved in distilled 
water and administered subcutaneously 30 min prior to test. Nifedipine 
(Orion Pharmaceutica, Finland) and BAY K8644 (Bayer, Germany) were 
suspended in distilled water, with 2-4 drops of Tween-80 and administered 
intraperitoneally 60 min and 15 min prior to test, respectively. Ethanol 
was administered intragastrally as 10% water solution 30 min prior to test 
The solutions of nifedipine and BAY k8644 were always made ex tempore 
and protected against light by storing in dark bottles wrapped tightly in 
aluminum foil. 
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Apparatus and procedures. The responsiveness of rats to painful 
stimulus was assessed using the hot plate test, [22, 23]. The plate surface 
temperature was maintained at 55.4* С and a cutoff time of 30 sec was 
imposed. Baseline testing was done prior to drug administration by 
recording the latency of response (licking of hind paws or jumping) in 
seconds. Animals were retested as for base-line testing after the drug 
administration. The analgesic data were expressed as "analgesic index" as 
described by Cox (1968). It is given by the formula (LQ^ $ - Lj)\(Lmlx -
L-)100 where LQ^1, Ц and Lmax are latencies (sec) after the treatment, 
initial latency and cutoff time respectively. 
Statistical analysis. The data were analyzed with analysis of vari­
ance (ANOVA) followed, where appropriate, with Duncan's multiple range 
test between individual groups. 
Results 
The effect of nifedipine on nociceptive response of the animals in the 
hot-plate test is shown in Fig. 1. The dose-response curve for nifedipine 
revealed that this dihydropyridine calcium channel antagonist produced 
a significant analgesic effect (F(5, 54) = 6.57; P = 0.0001) in the doses 2.5-20 
mg/kg. The lower dose of nifedipine tested (1.0 mg/kg) was ineffective. 
Muscimol (1 mg/kg s.c.), ethanol (2 g/kg i.g.) and baclofen (2.5-5 mg/kg 
s.c.) when administered alone produced analgesia in rats as it was evi­
denced by an increase in latency of analgesic response (Fig. 2-4). 
Nifedipine given in a low subanalgesic dose (1 mg/kg i.p.) significantly 
enhanced the analgesic response induced by 5.0 mg/kg baclofen (Fig. 2) 
but did not affect muscimol-induced analgesia (Fig. 3). Also, nifedipine (1 
mg/kg i.p.) tended to increase analgesic response induced by ethanol (1-2 
g/kg i.g.). However, the data were not significant (Fig. 4). Coadministra­
tion of a higher (analgesic) dose of nifedipine (10 mg/kg i.p.) with 
muscimol, baclofen and ethanol in the doses mentioned above (data not 
shown) resulted in an additive effect on nociceptive response latency. 
Dihydropyridine calcium channel agonist BAY K8644 neither en­
hanced nor decreased response latency time when given alone (data not 
shown). When BAY K8644 (0.1 mg/kg i.p.) was administrated in ethanol-
pretreated animals it significantly reduced ethanol (2 g/kg i.g.)-induced 
analgesia (Fig. 5). 
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Fig. 1. Effect of nifedipine on hot plate response latency in rat«. Each 
column represents mean ± SEM of 10 animal* per group. Nifedipine 
was administered i.p. 60 min prior to test. 
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Fig. 2. Effect of nifedipine (1 mg/kg) on baclofen-induced analgesia. 
Each column represents mean ± SEM of 10 animals per group. 
Nifedipine and baclofen were administered 60 and 30 min prior to test, 
respectively. 
# - P < 0.05 as compared to control saline group, 
* - P < 0.05 as compared to baclofen-treated group (multiple range test). 
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Fig. 3. Effect of nifedipine (1 mg/kg) on mutcimol-induced analgesia. 
Each column represents mean ± SEM of 10 animals per group. 
Nifedipine and muscimol were administered 60 and 30 min prior to 
test, respectively. 
* - P < 0.05 as compared to control saline group (multiple range test). 
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Fig. 4. Effect of nifedipine (1 mg/kg) on ethanol-induced analgesia. 
Each column represents mean ± SEM of 10 animals per group. 
Nifedipine and ethanol were administered 60 and 30 min prior to test. 
* - P < 0.05 as compared to control saline group (multiple range test). 
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Fig- 5. Effect of BAY K8644 on ethanol (2 g/kg)-induced analgesia. 
Each column represents mean ± SEM of 10 animals per group. Ethanol 
and BAY K8644 were administered 30 and 15 min prior to test, respec­
tively. 
* - P < 0.05 as compared to control group (multiple range test). 
Discussion 
A number of evidence suggest that intracellular calcium plays an 
important role in the regulation of nociception and also in the analgetic 
action of different drugs such as opiates [20], baclofen [12] and ethanol 
17]. 
In the present study, we found that DHP calcium channel antagonist 
nifedipine in a wide range of doses (2.5-20 mg/kg) exerts an 
antinociceptive effect in hot plate test. The observed analgesic effect of 
nifedipine is in agreement with previous studies, where it was found that 
calcium channel antagonists induce antinociceptive actions in mice when 
tested on the writhing induced by i.p. administration of acetic acid [6]. 
This effect of nifedipine is probably not linked to its vasodilatator effect 
since a potent non-calcium-blocking vasodilating drug, hydralazine does 
not produce analgesia in the hot plate test [2]. 
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A subanalgesic dose of nifedipine (1 mg/kg) when administered 
concurrendy with GABAg receptor agonist baclofen resulted in a potentia­
tion of baclofen-induced analgesia. As previously reported, baclofen acting 
at GABAg receptor either direcdy or indirectly affects calcium conduc­
tance [21]. On the other hand, co-administration of the same dose of 
nifedipine with САВАд receptor agonist muscimol did not produce any 
enhancement of antinociceptive effect of the latter. Muscimol has been 
proposed to increase chloride channel but not calcium channel conduc­
tance [13], therefore it could be speculated that the ability of nifedipine 
to enhance only baclofen- but not muscimol-iiiduced analgesia as well as 
an analgesic effect exerted by higher doses of nifedipine alone may be 
related to its potency to inhibit calcium current via the voltage-dependent 
calcium channels. However, it should be noted that while dihydropyridine 
binding sites in the CNS may indeed represent functional Ca^+ channels 
[18], inhibition of calcium conductances following the activation of 
GABAg receptors may be a result of enhanced efflux of potassium with 
no direct action on calcium channels, as it has been shown in patch-clamp 
studies [10]. Nevertheless, there is yet another possibility for 
dihydropyridine binding site and GABAg receptor interaction. Namely, 
since the L-type calcium channel, which is the target for DHP calcium 
channel antagonists, is functional only when phosphorylated by protein 
kinase A [3] it would be natural to expect the L-type calcium channel to 
be modified indirecdy by the GABAg receptor whose activation inhibits 
adenylate cyclase. 
After pretreatment with nifedipine (1 mg/kg), there was a slight 
enhancement of analgesic effect of ethanol (2 g/kg) which, however failed 
to meet the significance criterion. The dihydropyridine calcium channel 
agonist BAY K8644 ethanol-induced analgesia. This "antiethanol" effect of 
BAY K8644 taken together with the minimal enhancement of ethanol-
induced analgesia by nifedipine are in line with previous findings [8, 15] 
who showed that some behavioral effects of acute ethanol were augmented 
by calcium channel antagonists and reduced by calcium channel agonist 
BAY K8644. 
In conclusion, although the exact nature of the interaction between 
GABA receptor agonists and calcium channel-affecting drugs of the 
dihydropyridine class remains to be elucidated , results obtained in the 
present study suggest that GABAg receptors and dihydropyridine binding 
sites could be functionally linked in the regulation of nociception possibly 
via voltage-sensitive calcium channels. 
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CHANGES IN SENSITIVITY OF DOPAMINE 
AUTORECEPTORS AFTER SINGLE AND 
CHRONICMORPHINE ADMINISTRATION TO RATS 
T.Kivastik, A.Zharkovsky 
Department of Pharmacology, Tartu University 
Abstract 
Yawning behaviour induced by quinpirole (0.05 mg/kg SC) in rats 
was used in order to study the state of dopamine (DA) autoreceptors after 
a single and chronic morphine administration. Acute morphine treatment 
(3.0 mg/kg SC) was given 15 and 90 minutes before assessment of yawning. 
Acute 15 minutes morphine pretreatment significantly inhibited yawning. 
On the contrary, acute 90 minutes pretreatment and chronic morphine 
administration significantly enhanced yawning. DA D1 receptor antagonist 
SCH23390 (0.01 mg/kg IP) given in combination with acute 90 minutes 
pretreatment, significantly increased the rate of yawning but failed to alter 
it in other experiments. DA D1 agonist SKF38390 in the dose 1.25 mg/kg 
had no significant influence on quinpirole induced yawning. The data 
obtained allow to conclude the state of supersensitivity of DA 
autoreceptors following single morphine administration (90 minutes 
pretreatment) and chronic morphine treatment. 
Introduction 
The biochemical and pharmacological evidence indicates the presence 
of two families of dopamine (DA) receptors, designated as Dl-like and D2-
like (12). The D1/D2 classification scheme is based primarily on the 
findings that D1 receptors arc those which are linked positively to adenyl­
ate cyclase system whereas D2 receptors are not linked or inhibit this 
enzyme (5). The D2-like family contains D2, D3 and D4 subtypes (12). In 
addition to subdividing DA receptors on the pharmacological profile, one 
can also distinguish such receptors on the basis of their anatomical 
location. At least three DA receptors have been identified in this manner 
postsynaptic receptors in apposition to DA nerve terminals, nerve terminal 
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autoreceptors which modulate the synthesis and/or release of DA, and 
somatodendritic DA autoreceptors which regulate impulse flow in DA 
neurons by controlling K+ conductance (7). DA auotoreceptors exhibit the 
pharmacological characteristics of DA D2-like receptors (16). Low doses of 
DA D2 receptor agonist preferentially affect DA autoreceptors and their 
activation is thought to induce sedation, sleep and yawning that reflects 
the inhibition of dopaminergic transmission (3,15,18). 
It has been suggested that acute or chronic administration of mor­
phine to rats could induce supersensitivity of postsynaptic DA receptors 
(10, but see also 6). As for DA autoreceptors, previous findings suggest 
rather a diminished DA autoreceptor control caused by morphine (2,3,16). 
Ahtee et al. (1989) demonstrated that withdrawal from chronic morphine 
administration decreased a striatal and limbic DA turnover, the challenge 
dose however, could increase it in withdrawn rats as well as in control 
group (3). 
The aim of the present study was to investigate the state of DA 
autoreceptors after single and chronic morphine administration. As a 
behavioural model of activation of DA autoreceptors in rats yawning 
behaviour was used (but see also 9 and 11). Series of experiments (see table 
1) was done in order to study the effect of acute and chronic morphine 
treatment (morphine alone and in combination with cither DA,D1 
selective agonist SKF38393 or DA D1 selective antagonist SCH23390) on 
yawning behaviour induced by DA D2/D3 agonist quinpirole 
(LY171555)(13). Taking into consideration biphasic effect of morphine on 
locomotion in which DA receptors may have an essential role (9) yawning 
was assessed at various times (15 and 90 minutes) after acute morphine 
treatment 
Materials and methods 
Animals: the experiments were carried out on male albino laborato­
ry rats (Rappolovo Farm St Petersburg) weighing 210-280g. The animals 
were kept in groups of 8-10 per cage and were given food and water ad 
libitum. 
Drug«: Morphine Hydrochloridejwas dissolved in saline and injected 
SC (0.2 ml/l00g) in the neck region (doses were calculated as a base). 
Quinpirole Hydrochloride (Lyl71555) was dissolved in saline and injected 
0.05 mg/kgSC(neck region). SCH23390 [R-(+)-8-chloro-2,3,4,5-tetrahydro-3-
N-methyl-5-phenyl-l H-3-benzodiazepine-7-ol hemimaleate; gift from 
Schering Corp., Bloomfield, USA] - was dissolved in a small amount of 
4 
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glacial acid and diluted with saline and injected 0.01 mg/kg IP 15 minutes 
before quinpirole injection. SKF38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-l-
phenyl-l H-3-benzazepine HCl; Smith, Kline and French Lab, Philadelphia, 
USA) was dissolved in warm saline and injected 1.25 mg/kg IP 5 minutes 
before quinpirole. 
Takle I. Experiments done in order to investigate the state of DA 
autorecptors after acute and chronic morphine administration. 
Abbreviations: Valine, M-morphine, SCH-SCH23390, SKF-SKF38393, 
Qfluinpirole. 
Experiment Morphine treatment Groups 
El single dose 
15 min. before 
test 
SSQ_ 
S-SCH-Q^ 
M-S<L 
M-SCH-Q. 
E2 single dose 
90 min. before 
test 
SSQ_ 
S-SCH-Q_ 
M-S-Q, 
M-SCH-Q^ 
E3 single dose 
90 min. before 
test 
SS-Q. 
S-SKF-Q^ 
M-S-Q 
M-SKKL 
E4 chronic treatment, 
challenge dose given 
90 min. before test 
SS-Q. 
SSCH-Q. 
M-S-Q 
M-SCH-Q 
To assess yawning the rats were placed into individual plexiglass boxes 
of 15X15X15cm 20 minutes before morphine injection. The number of 
yawns was counted during 30 minutes after quinpirole injection with a 
hand held counter. 
Acute morphine administration experiments were arranged in 
randomized blocks: 32 male rats for each experiment were randomly 
divided into 4 groups (Table 1; n=8 per group) and during 4 days the tests 
were carried out (i.e. 2 animals from each group a day). When adminis­
tered acutely morphine was given 3.0 mg/kg SC All tests were carried out 
between 2-5 p.m. 
14 
Chronic morphine treatment 32 male rats were randomly 
divided into 4 groups (Table 1; n=8 per group). Two groups received 
chronic morphine treatment and the remain of animals were administered 
chronically saline (0.2 ml/100g). Morphine and saline were given twice a 
day (8-9 a.m. and 4-5 p.m.) for 8 days, morphine in increasing daily doses: 
20-30 mg/kg SC The tests were carried out on the 9-th day between 2-5 
p.m. (i.e. about 21 hours after the last injection). 90 minutes prior to 
assessment of yawning 3.0 mg/kg morphine was given to rats from mor­
phine groups. 
Statistical analysis: B*perimental data organized in randomized 
block design were subjected to multifactor ANOVA The experiment days 
(with 3 d.f.) were used as blocks. Two-Way ANOVA for chronic treatment 
was used. Post hoc multiple comparison was done using Tukey HSD test 
Results 
Acute morphine adsninietration: In El ANOVA revealed signifi­
cant effect of 15 minutes morphine pretreatment [F(l,25)=28.4, p<0.0001] 
and nonsignificant effects of SCH23390 and morphine X SCH23390 
interaction. Further multiple comparison showed significantly »lower 
number of yawns both in gfoups M-S-Q_and M-SCH-Q_than in group S-S-
Q_(fig.l). In group S-SCH-Q_thc number of yawns was slightly lower than 
in group S-S-Q. 
On the contrary, 90 minutes morphine pretreatment significantly 
enhanced yawning both in E2 and in E3. By ANOVA was established 
significant effects of morphine [E2: F(l,25)=20.9, p<0.001; E3: F(l,25)=6.38, 
p<0.05]. In E2 ANOVA revealed also significance of SCH23390 
[F(l,25)=4.9, p<0.05] and significant morphine x SCH23390 interaction 
[F( 1,25=8.4, p<0.01]. Further multiple comparison revealed significantly 
higher number of yawns in group M-S-Qjversus other groups (fig.2). The 
number of yawns was slightly lower in group S-SCH-Q_than in S-S-Q^ In 
E3 ANOVA yielded nonsignificant effect of SKF38393. When compared 
with S-S-Qi in group S-SKF-Q_yawning was slightly enhanced (fig. 3). 
Chronic morphine treatment (fig. 4) significantly enhanced 
yawning behaviour, Two-Way ANOVA revealed significance of morphine 
[F(l,26)=6.3, p<0.05], nonsignificant effects of SCH23390 and morphine 
x SCH23390 interaction. 
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Fig. 1. Effect of 15 min. morphine pretreatment (3.0 mg/kg SC) and 
SCH23390 (0.01 mg/kg IP) on yawning induced by quinpirole (0.05 
mg/kg SC). Each bar represents the mean ±SEM. 
Abbreviations: 
S - saline, M - morphine, SCH - SCH23390, Q_- quinpirole. 
*p<0.05 vs. group S-S-Q_(Tukey HSD test). 
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Fig. 2. Effect of 90 min. morphine pretreatment (3.0 mg/kg SC) and 
SCH23390 (0.01 mg/kg IP) on yawning induced by quinpirole (0.05 
mg/kg SC). Each bar represents the mean ±SEM. 
Abbreviations: 
S - saline, M - morphine, SCH - SCH23390, Q- quinpirole. 
*p<0.05 vs. other groups (Tukey HSD test). 
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Fig. 3. Effect of 90 min. morphine pretreatment (3.0 m&^kg SC) and 
SKF38393 (125 mg/kg IP) on yawning induced by quinpirole (0.05 
mg/kg SC). Each bar represents the mean ±SEM. 
Abbreviations: 
S - saline, M - morphine, SKF - SKF38393, Q_- quinpirole 
50 г 
40-
S-S-Q S-SCH-Q M-S-Q M-5CH-Q 
Fig. *. Effect of chronic morphine treatment and single administration 
ofSCH23390 (0.01 mg/kg IP) on yawning induced by quinpirole (0.05 
mg/kg SC). Each bar represents the mean ±SEM. 
Abbreviations: 
S - saline, M - morphine, SCH - SCH23390, Q_- quinpirole. 
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Discussion 
Acute 90 minutes morphine pretreatment significantly potentiated 
yawning induced by quinpirole. These results are interesting because 
previous findings suggest rather a subsensitive ;tate of DA autoreceptors 
following morphine administration (1,2,16). Thus morphine has been 
shown to stimulate the firing of A10 DA cells leading to enhanced release 
of DA within the nucleus accumbens. Besides the subsensitivity of DA 
autoreceptors morphine has been shown to have direct inhibitory effects 
on the non-DA neurons in ventral tegmental area (VTA) that leads to 
inactivation of inhibitory GABA-ergic neurons within the VTA (4,8). In 
the present study stimulating effect on yawning of 90 minutes morphine 
pretreatment could be observed in two experiments (E2 and E3) thus, 
taking into consideration the autoreceptor origin of yawning a 
supersensitivity state of DA autoreceptors may be concluded. 
A single dose of morphine given 15 minutes before test however 
inhibited yawning. One may explain it with concomitant increase of 
postsynaptic DA D1 receptors that exert inhibitory effect over DA 
autoreceptors mediated behaviours (18) but the opposite effects of acute 
15 and 90 minutes pretreatment remain however, unclear. It has been 
shown the biphasic effect of morphine on locomotion: an initial hypomo-
tility followed by hypermotility in which DA D1 receptors have an essen­
tial role (9). Hence, one should have presumed an enhanced influence of 
DA D1 receptors 90 minutes after morphine administration versus 15 
minutes pretreatment and so results of the present study were an opposite 
kind to what could be expected. 
DA D1 receptor antagonist SCH23390 when given in combination 
with 90 minutes morphine pretreatment significantly enhanced yawning 
(E2). These data are consistent with earlier studies that demonstrated the 
opposing role of D1 and D2 receptors in the regulation of yawning 
behaviour induced by low doses (0.025-0.15 mg/kg) of apomorphine (18). 
Interestingly in other experiments of the present study (El and E4) 
SCH23390 failed to alter yawning or even seemed to slightly decrease it, 
and just the opposite trend (slight increase of yawning) could be observed 
as the effect of DA D1 agonist SKF38393 in E3 [Morelli et al. (1986) 
demonstrated that SCH23390 given 0.05 mg/kg could antagonize yawning 
induced by apomorphine (11) and Spina et al. (1989) showed potentiating 
effect of SKF38393 on quinpirole induced yawning (14). Proceeding from 
those data the investigators concluded postsynaptic origin of this 
behavioural syndrome]. 
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Chronic morphine treatment enhanced yawning induced by 
quinpirole. Although it has been shown that repeated opioid treatment did 
not cause tolerance to the opioid-induced increase of brain (except hypo­
thalamus) DA turnover (2), it is very likely that in the present study the 
challenge dose of morphine (3.0 mg/kg) was too low in this respect. Then 
the data obtained are consistent with the earlier findings about decreased 
synthesis and release of striatal and limbic DA during morphine with­
drawal. 
Taken together, since yawning syndrome of rats is generally thought 
to be mediated via activation of presynaptic DA receptors (3,15,18), our 
results suggest that a single dose of morphine and withdrawal from chron­
ic treatment could induce a supersensitivity state of DA autoreceptors. 
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Abstract 
Central cholecystokinin (CCK)-ergic neurotransmission has been 
implicated in the genesis of negative emotions. Most animal studies on the 
neurochemical background of CCX-induced anxiety have, up to date, 
exploited exploratory activity paradigms. Some recent studies, however, 
have demonstrated that other paradigms of anxiety are also sensitive to 
CCK receptor agonists and antagonists. The interaction of CCK with 
GABAergic inhibitory neurotransmission, mediated probably through 
CCK-B receptors, could be the neurochemical substrate for aiycious 
behavioural pattern. However, the CCK-A and CCK-B receptor-mediated 
interactions of this neuropeptide with mesencephalic dopaminergic regula­
tion of motivation for locomotor activity have the potential to interfere 
with the behavioural outcome from routine exploratory activity tests. 
Systemic treatment with CCK receptor antagonists is likely to influence 
both GABA- and dopamine-linked CCK-ergic neurotransmission, and 
therefore their effects in exploratory activity tests should be interpreted 
with caution. 
Considerable amount of evidence is now available to suggest that 
cholecystokinin (CCK) can act as a neurotransmitter in the central ner­
vous system [8], the octapeptide fragment (CCK-8) 
being the predominant form of this peptide in the brain [51]. Neuronal 
CCK has been proposed to play a significant role in feeding [44], pain 
perception [3], memory [35] and sedation [62]. CCK exerts its effects 
through interaction with specific receptors, that are currently divided into 
two subtypes: CCK-A receptors in viscera and in a limited number of 
brain regions, and CCK-B receptors that are widely distributed in the 
brain [18,43]. Whereas the initial discrimination between "peripheral and 
central" CCK receptors was based on the selectivity of unsulfated CCK-8 
aud shorter CCK fragments for "central" or CCK-B receptors, selective 
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nonptptide antagonists for both receptor suntypes have been developed 
during the last years [21,34] which enable analyses of the contribution of 
both receptor subtypes in the regulation of behaviour. 
CCK hypothesis of anxiety 
Recently, neuroscientists have been fascinated by the idea that CCK 
might be an endogenous anxiogenic [50]. Indeed, CCK-related peptides 
have been shown to elicit anxiogenic-like effects in rodents 
[12,13,14,19,30,31]. CCK-8, caerulein, pentagastrin and CCK-4 have been 
used in these studies. The stimulation of CCK receptors can induce 
conditioned taste and place aversion, facilitate defensive burying, and 
impair exploratory behaviour in rodents. Moreover, cholecystokinin 
tetrapeptide (CCK-4) was recently characterized as a panicogenic agent in 
humans, being active in healthy volunteers [15] but especially potent in 
panic disorder patients [6]. This effect of CCK-4 is also shared with 
pentagastrin (CCK-5) [1]. 
Although distinct experimental approaches to study anxiety in 
animals are possible, not all of them can be equally favoured in the case 
of CCK. As a matter of fact, CCK exerts potent and complex anoretic 
effects which discourage the use of methods that are based on food or 
water motivation. Most studies have been designed to characterize the 
influence of CCK receptor ligands upon neophobic behaviour in several 
exploratory activity tests. However, the shortcoming of these techniques is 
the difficulty in making a clear distinction between behavioural reflections 
of changes in anxiety state and in general locomotor activity [24]. The 
latter depends strongly on the motivation of the animal to move fiom'one 
place to another. Therefore anxiety induction, that is supposed to shift the 
ratio between exploratory and fear drives, may decrease exploration (as 
expected) only if such a motivation exists but is not too vital. On the 
other hand, extreme fear may cause startle reactions and an increase in 
locomotion measures (especially if the test time is short to avoid the effect 
of habituation) that must naturally not be attributed to anxiolysis. 
It has been recognized for several years that CCK-peptides can depress 
exploratory activity, but perhaps due to their well-characterized sedative 
action [62], this was not usually interpreted as an anxiogenic action (what 
it, in most studies, probably wasn't, but in few cases possibly was). Recent­
ly, the decrease in exploratory activity after treatment with CCK-peptides 
has been observed in the elevated plus-maze test [12,13,23,26,31,53,58], by 
now one of the most popular anxiety measures [49]. 
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Table 1 summarizes our data on the influence of some CCK-peptides 
on rat exploratory activity in two tests. It is clear that CCK-B receptors 
mediate the anxiogenic action of CCK in this species, whereas the stimula­
tion of CCK-A receptors might be responsible for the more gross changes 
in general activity. Among these peptides, there is a high positive correla­
tion between the affinity for CCK-B receptor and the potency as an 
anxiogenic [58]. Accordingly, CCK receptor antagonists should increase 
exploratory activity. Consistently, devazepide and L 365,260 are reported 
to display such an anxiolytic profile in plus-maze test [50], and similar 
effects have been obtained with the drugs recently synthetized at Parke-
Davis that represent a chemically distinct class of CCK-B receptor antago­
nists [34]. In our laboratory, we have not been able to observe any 
anxiolytic-like effect of devazepide or L 365,260 as a single pharmacological 
treatment in elevated plus-maze test, however, both of these drugs (as well 
as proglumide and lorglumide) blocked the anti-exploratory action of 
CCK-4 (Table 2). Comparison of minimal effective doses of the CCK 
receptor antagonists against CCK-4 leaves little doubt that their action 
involves CCK-B receptors [31]. 
Tabic 1. Minimal effective doses of CCK receptor agonists in two 
behavioural tests: comparison with GABA-negative drugs 
Drug Receptor subtype Elevated Open field 
selectivity plus-maze 
Caerulein A 8c В 100 ng/kg 5 gg/kg 
Pentagastrin 
В 
500 ng/kg > 100 gg/kg 
CCK-4 
В 25 ng/kg > 200 ng/kg 
DMCM 0.3 mg/kg 1 mg/kg 
Pentylenetetrazol 15 mg/kg 25 mg/kg 
Elevated plus-maze test was performed according to the conventional 
methods [22,44] with minor modifications [24]; open field was a simple 
arena lxl m divided into 16 equal quadrants [24]. Parameters registered: 
plus-maze test, a) number of crossed sectors in the open part of the 
maze and b) time spent in open arms; open field test, a) number of 
crossed sectors and b) number of rearings. Minimal effective doses were 
defined as the doses which, 15 min after subcutaneous administration, 
decreased significantly (Mann-Whitney test, P<0.05) at least one of the 
two measures taken in a test 
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CCK interaction with GABA 
Ai far as the anxiety-related ? tloni of CCK receptor ligands assume 
direct interaction with central GAßAergic neurotransmission, the CCK 
receptor subtype might weil be the CCK-B receptor evidence for 
ЙЛВЛ/ССЖ-8 interactions comes from the studies of those brain regions 
(cerebral cortex, hippocampus) [5,27,30,61] whee CCK-A receptors arc not 
known to exist but CCK-B sites arc rather abundant. Interestingly, these 
are also the brain regions where colocalization of GABA and CCK 8 has 
beefa described, whereas all or nearly all CCK-immunopositive neurons in 
these area* also synthetize GABA [32,37,54]. In the cerebral cortex, the 
release of CCK appears to be under tonic GABAergic control: not only 
GABA inhibits CCK release, the picrotoxin treatment can augment it In 
hippocampus, CCK elicits fast excitatory postsynaptic potentials that can 
be blocked completely by low doses of benzodiazepines. More recently, 
coexistence of GABA and CCK was detected in the amygdala, another 
limbic structure [40], which could be the site of anxiogenic-like promnestic 
action of CCK-8, an effect that can be attenuated by benzodiazepine 
treatment [19]. 
Table 2. CCK receptor antagonists and exploratory activity of 
rats in the elevated plus-maze 
Drug Receptor 
subtype 
selectitivty 
Previous anxiogenic treatment 
None CCK-4 
50 gg/kg 
Pictrotoxin 
0.5 mg/kg 
Pipghimide 
Lorgiumide 
Devazepide 
L 365,260 
LY 288613 
A 8c В 
A 
A 
В 
В 
1 mg/kg 
0.1 mg/kg 
1 m^kg 
10 #tg/kg 
not tested 
10 mg/kg 
not tested 
CCK receptor antagoniste were given 5 min (proglumide) or 15 min (all 
others) before challenge with angiogenics. Minimal active doses are given 
in the table - indicates the lack of effect. For further comments see the 
footnotes for Table 1. 
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In one study rats displaying anxious or non-anxious type of explor­
atory behaviour in plus-maze when tested in an undrugged state were 
separated into respective subgroups and radioligand binding to СХЖ-8 and 
benzodiazepine receptors was compared between these subgroups as well 
as to home-cage controls [26]. The results revealed that in anxious and 
non-anxious animals, a brief episode of forced exploration induced chang­
es in receptor binding in these brain regions where CCK-8/GABA coexis­
tence is observed (frontal cortex, hippocampus). These changes were 
different in anxious and non-anxious subgroups, further suggesting that 
СХЖ-В receptors are involved in anxiety-related alterations of exploratory 
behaviour. Moreover, pharmacological anxiogenic manipulations at GABA 
receptor complex (challenge with GABA-negative, drugs at anxiogenic doses 
and diazepam withdrawal) also affect CCK-B receptor binding [26,27]. 
Elevated plus-maze test is not * simple anxiety test 
However, during the past few years, besides the GABA hypothesis of 
anxiety, several other neurochemical mechanisms, most prominently 
serotoninergic ones, have been shown to be of major importance. Accord­
ingly, it has been suggested that different aspects of anxiety deserve more 
attention and, perhaps, distinct animal models [22]. A very clear warning 
not to overemphasize the value of the studies on exploratory activity in 
the plus-maze test for understanding the brain mechanisms of anxiety 
comes from the evidence that azaspirodecandione anxiolytics (e.g, 
buspirone) show anxiogenic, if any, effect in this paradigm. Furthermore, 
according to the conventional characterization of the test [49], anxiety is 
expected to influence only few meassures in plus-maze, namely the percent­
ages of open arm visits and time spent in open arms from total number 
of arm visits and total duration of the test, respectively. However,earlier 
[24] as well as recent [46] studies have shown that decrease in the total 
number of arm entries should not always be considered as a sign of a non­
specific depression of activity. Indeed, for an aroused rat, the central 
platform of the plus-maze may frequently be a too dangerous place to 
enter. In open-field tests, there rab do not necessarily display any decrease 
in activity and there is no correlation between spontaneous activity of rats 
in elevated plus-maze and open field (our unpublished observations). The 
importance of central platform behaviour in mice was recendy underlined 
and it was demonstrated that the platform was more aversive than the 
areas protected with walls [38]. Moreover, at certain doses diazepam may 
enhance the total number of entries [24], probably reducing the 
aversiveness central area. 
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The version of plus-maze most extensively used currently [24], after 
its minor modification and complex validation as a measure of anxiety 
[49] has been modified several timcj) e.g. by dividing the open arms into 
sectors to be counted as an index of open arm exploration [7,26]. It is 
notable that two groups of researchers in preclinical psychopharmacology 
independently have tried a similarly distinct approach from the established 
method. The conventional plus-maze test presumes that the open area is 
most fear-prövoking when all the animal's four legs are out of closed arms 
as well as central platform. However, if the animal is really afraid of the 
open area, it will not enter the open arms placing all its four legs on it 
making the percentage calculations invalid (the number of entries into 
closed arms may vary in a great extent). Such a rat should not appear to 
be sedated and can approach the central platform several times [45]. The 
ratio of open arms entries and approaches to the central platform might 
therefore be more relevant index of anxiety in plus-maze, decreasing the 
problem of obtaining false negatives with anxiogenic drugs taken as 
sedatives. It even seems to fit best with the very first presentation or the 
idea of such an anxiety test [42], as the novel stimulation evokes "both the 
fear drive and the exploratory drive, thus generating an approach-avoid­
ance conflict". 
Focus on motivation: CCK and dopamine 
The interest of neuroscientific community into neuronal CCK 
increased abruptly when CCK was demonstrated to colocalize with dopa­
mine in a subpopulation of mesencephalic nerve cells, which innervate 
mesolimbic and cortical regions [29]. Studies on the interaction of CCK 
and dopamine in these neural pathways have been proceeding continuous­
ly. It is therefore regrettable that research directed at the role of CCK in 
anxiety is, despite taking advantage of exploration tests, missing the 
influence that CCK-peptides and CCK receptor antagonists might have on 
the dopaminergic mechanisms that are believed to possess a profound 
impact on motivations. Indeed, dependence-producing drugs increase DA 
release in nucleus accumbens (NAcc) [17] and increase locomotor activity, 
probably by activating mesolimbic DA system [55,57,60]. 
Considerable interest has been devoted to the role of NAcc in the 
CCK modulativii о/ locomotor activity as this brain region is suggested 
to be the specific site for the action of CCK-peptides [36]. Administration 
of CCK-8 directly into NAcc may lead to either an increase [11] or de­
crease [ 10,20,36] in the locomotor activity of rats. CCK-8-induced decreases 
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in locomotion arc elicited through CCK receptors in the posteromedian 
part of NAcc which probably are of CCK-A subtype [12,13,14]. The 
behavioural effect is dependent on the motivational state of the animal, 
as CCK-8 decreased activity only in rats that were not habituated to the 
environment [13]. Indeed, intra-NAcc CCK potentiates DA action, having 
no effect alone [9]. The behavioural effects of CCK-8 and CCK-4, the 
unselective and B-subtype selective agonists respectively, after administra­
tion into NAcc, are clearly opposite: in the studies where CCK-8 was 
described to decrease locomotor activity [36] or intracranial self-stimula­
tion [16], CCK-4 increased both. The neurochemical mechanisms that 
cause such an opposite regulation of behaviour via distinct receptor 
subtypes arc not precisely identified, but recently it was demonstrated that 
CCK has a dual action on potassium-stimulated dopamine release from 
NAcc, causing an increase in dopamine release via CCK-A receptors and 
decrease via CCK-B receptors [39]. The latter effect may be the basis for 
the anti-amphetamine effect of CCK-8 in NAcc [9], whereas potentiation 
of DA-induced hyperlocomotion, probably CCK-A-mediated action, 
implies modulation of postsynaptic DA receptors. 
In one important study [19], the ability of CCK-8 to induce 
behavioural arousal was linked amygdala, whereas its neuroleptic-like 
effects were associated with nucleus accumbens. The importance of NAcc 
in the integration of limbic output to locomotor behaviour is generally 
recognized [41], An intriquing question is how the NAcc-con trolled 
locomotion is linked to the effects of anxiety on exploration measures. 
Present knowledge supports the hypothesis, according to which CCK has 
multiple roles in the regulation of exploratory behaviour. 1) in the brain 
regions, where it colocalizes with GABA it participates in the genesis of 
anxiety; 2) in NAcc, it modulates the DA-dependent motivational control 
over ongoing behaviour. These two CCKergic systems may be interrelated, 
for example, through excitatory input to NAcc from amygdala and hippo­
campus that has been shown to decrease exploratory activity [41]. Interest­
ingly, the basolateral nucleus of amygdala, one of the sources of this input, 
has been suggested to be a site of action for benzodiazepine anxiolytics 
[52] and is one of the regions of GABA/CCK coexistence [40]. 
From Table 2, it is apparent that only proglumide (the unselective 
CCK receptor antagonist) reliably blocked the anxiogenic-like effect of 
Picrotoxin on exploratory activity. The explanation for this can be derived 
from the above hypothesis, suggesting that the blockade of both CCK-A 
and CCK-B receptors that participate in GABA/CCK and DA/CCK 
interactions might be necessary. This is in accordance with the idea that 
Picrotoxin can reduce exploratory drive at the same time as enhancing fear 
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[24]. Tbc primary importance of CCK-B receptor blockade is simple to 
derive from most of the studies conducted to date; however, this leaves 
open the possibility of an action of CCK-8 On CCK-A receptors in pos­
teromedian NAcc, shown to decrease exploration in novel environment 
[13]. 
Other neurotransmitters involved? 
It is certainly inappropriate to restrict attention only to the interac­
tion of neuronal CCK-ergic activity with GABA and dopamine. For 
example, nucleus accumbens receives afferents from 5-HT-ergic dorsal 
raphe cells [56], and most recently an excitatory influence of CCK-8 on 5-
HT neurones in the rat dorsal raphe has been demonstrated [4]. The 
receptors mediating this effect of CCK-8 appear to be of CCK-A subtype 
and could, in parallel to peripheral CCK-A receptors [48], serve as a target 
for the sedative action of CCK-peptides. We have recently been able to 
demonstrate, that the anti-exploratory effect of caerulein can be attenuated 
by ondansetron, a representative 5-HT-3 receptor antagonist [59]. Since this 
effect was observable only in a limited dose range, interference with 
general locomotor effects should also be considered here. As a matter of 
fact, lower doses of ondansetron had diminishing influence on locomo­
tion, possibly masking the anti-anxiety action. 
Another alley yet to be explored is the interaction between CCK and 
noradrenaline. If NA-ergic nerve terminals arc damaged by treatment with 
DSP4, the neurotoxin that selectively damages the projections from the 
locus coeruleus, surprisingly few changes can be observed in gross 
behaviour. What has consistently been shown to change, however, is the 
exploratory behaviour and adaptation to novelty. Since the upregulation 
of CCK receptor binding in the rat frontal cortex has been correlated with 
deficits in plus-maze behaviour, it was of interest to investigate the possi­
bility that the degeneration of the locus coeruleus input leads to alter­
ations in the CCK receptor binding abilities. This has indeed turned out 
to be the case [25]. DSP-4 treatment caused, in a dose-dependent manner, 
significant increase in the density of CCK-8 binding sites in those brain 
regions, that receive their major NA-ergic input from the locus coeruleus 
(frontal cortex, hippocampus), but not in those, where there arc few locus 
coeruleus projections (hypothalamus, corpus striatum). The time-course of 
the development of changes in CCK-8 binding paralleled with some lag the 
development of changes in noradrenaline uptake, whereas desipramint 
pretreatment abolished both. These findings demonstrated that denervation 
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of noradrenergic input from the locus coeruleus induces certain alterations 
in the CCK-ergic neurotransmission, similar to those seen in rats with 
deficits in response to novel stimuli. CCK could therefore mediate the 
neophobic responses observed in animals after lesions of noradrenergic 
innervation of the forebrain. 
CCK end suicide 
There is significant overlap between panic disorder and self-destruc­
tive behaviour, and also other anxiety disorders and suicide [47]. Among 
the dimensions of personally, related to suicide, susceptibility to 
fear/anxiety appears, but according to a psychobiological model of self 
destructive behaviour, suicide is unlikely to occur even in a highly vulnera­
ble individual unless the person finds himself in a situation which he/she 
conceives as desperate [2]. Suicidal behaviour could, thus, be categorized 
as an ultimate desadaptation with environmental changes. Animal research 
had led us earlier to suggest that high density of CCK receptors in cortical 
regions might be a basic biological correlate of deficits in adaptation with 
environment [26]. Thus, one might wonder whether brail). CCK-ergic 
transmission is affected in suicidal persons. This question was addressed 
in a study carried out on post-mortem brain samples from 19 suicide 
victims and 23 well matched control cases [28]. In the frontal cortex, 
significantly higher apparent number of CCK receptors and affinity 
constants were found in the series of suicide victims. These differences 
between suicides and controls were present in similar proportions when 
the suicide cases with depressive syndrome or violent or non-violent means 
of self-killing were compared to matched controls. However, when the 
samples were split into subgroups consisting of persons cither below or 
over the age of 60 years, significant differences in the CCK receptor 
characteristics in the frontal cortex were observed only between younger 
suicides and controls. Furthermore, the younger suicide victims had a 
higher density of CCK receptors in the cingulate cortex, whereas in older 
suicides the value was lower as compared to age-matched controls. It 
should be noted that the cortical CCK receptor binding basically does not 
change neither in aged rats nor in aged humans [28,29]. No difference in 
benzodiazepine receptor binding was found between control and suicide 
groups. The results of this investigation suggest that CCK-ergic 
neurotransmission is linked to self-destructive behaviour, probabaly 
through its impact in anxiety and adaptational deficits. Since severe 
anxiety, at variance with depression, is uncommon in the elderly, and 
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panic disorders is very rare among the old people, CCK might well have 
distinctr roles in the neurochemistry of self-destructive behaviour in 
different age groups. 
CCK agonists as anxiogcnics of choise for further research? 
CCK-B receptor agonists offer one clear advantage as test anxiogcnics. 
As far as conventional anxiogenic drugs also possess (at higher doses) a 
potential for convulsant action, increasing the dosage has usually resulted 
in further decreases in gerneral activity, possibly due to effects rather 
unspecific to exploratory drive. CCK-B agonists, however, appear to 
represent a group of drugs that may induce anxiety and perhaps increase 
neophobia, but do not decrease the motivation to move and do not 
prevent the animal from changing location. CCK-4 has also turned out to 
be a safe and efficient anxiogenic for the humans, especially potent in case 
of clinically detectable emotional disturbances. 
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Abstract 
The role of CCK receptors in the development of anxiety caused by 
social isolation of rats was studied using the elevated plus-maze and 
receptor binding techniques. The isolation of male Wistar rats significantly 
reduced their exploratory activity in the elevated plus-maze compared to 
that in the rats kept in groups of four. Caerulein (0.1-5 ^g/kg s.c.), an 
agonist of CCK receptors, dose-dependently decreased the exploratory 
activity in the plus-maze test of the rats housed in groups, but not that of 
single rats. Caerulein even tended to increase the behavioural activity of 
isolated rats. 
In parallel to the behavioural changes, isolation of the rats increased 
the number of [3H]pCCK-8 binding sites in the frontal cortex, but not in 
the other forebrain structures (the mesolimbic area, striatum and hippo­
campus). Isolation did not affect the density of benzodiazepine receptors 
in the frontal cortex. 
In conclusion, the isolation of rats for 7 days produced anxiogenic-
like effect on the behaviour of rats and increased the number of CCK-8 
receptors in the frontal cortex without affecting benzodiazepine receptors. 
Key words: Isolation - Caerulein - CCK receptors - Benzodiazepine 
receptors - Rat 
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Introduction 
Compared to the rats kept in social groups, isolated rats have various 
behavioural disturbances, like increased locomotor activity in an open 
field test and deficits in both learning and spatial memory tasks (Morgan 
et al. 1975; Sahakian et al. 1977; Morinan and Parker 1985). In addition, 
the exploratory activity of these animals is markedly decreased in the 
elevated plu*maze (Wright et al. 1990). In the white-black box preference 
test, animals spend most of their time in the dark compartment (Morinan 
et al. 1992). 
Significant alterations in dopaminergic and serotonergic transmission 
in various brain structures of isolated rate have been shown. Isolated rats 
show greater increases in the frontal cortex dopamine metabolism in 
response to foot-shock (Blanc et al. 1980). Dopamine release stimulated by 
amphetamine is also augmented (Jones et al. 1988) compared to the 
animals kept in groups. Enhanced efflux of cortical serotonin to local 
application of KCl or systemic treatment with fenfluramine has been 
reported in isolated rats (Crespi et al. 1992). In contrast, the density of 
benzodiazepine receptors remains unaffected by social isolation (Morinan 
et al. 1992). 
Recently the role of cholecystokinin (CCK) has been established in 
the regulation of anxiety-related states in laboratory animals and man 
(Ravard and Dourish 1990; Harro and Vasar 1991b). The administration 
of CCK-4, an agonist at the central subtype of CCK (CCKg) receptors, 
suppressed the exploratory activity of rats in the elevated plus-maze test 
(Harro and Vasar 1991a). CCK-4 also induced panicogenic effect in the 
man (Bradwejn et al. 1990). The selective CCKß antagonist L-365,260 has 
been demonstrated to reverse the anti-exploratory (Harro and Vasar 1991a) 
and panicogenic actions of CCK-4 (Bradwejn et al. 1992). Taking into 
account these observations an attempt was made to study the role of CCK 
receptors in the development of suppression of exploratory behaviour after 
the social isolation of rats. Since CCK and GABA have obvious functional 
and morphological interactions (Somogyi et al. 1984; Bradwejn and De 
Montigny 1984) the properties of the benzodiazepine receptors were also 
studied. 
Materials end Methods 
Animals. Male Wistar rats, weighing 180-200 g at the beginning of 
experiment, were caged individually or in social groups of four. 
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Behavioural testing of both groups, as well as collecting of brain samples 
for radioligand binding studies, took place 7 days following the different 
housing. 
Elevated plus-maze The method initially described by Handley 
and Mithani (1984) for measuring of exploratory activity in rats was used 
with some modifications (Harro et al. 1990c). Briefly, the plus-maze 
consists of two opposite open arms (50x10 cm) without side walls and two 
enclosed arms of the same size with 40 cm high side walls and end wall. 
The arms extended from a central platform (10 x 10 cm) and were angled 
at 90^ to each other, making a shape of a plus sign. To determine the 
exploratory activity in the open part of plus-m?ze the pair of open arms 
(together with the central platform area) was divided by lines into 7 equal 
squares. The maze was elevated to the height of 50 cm. During a 5 min 
observation session the following measures were taken by observer 1) 
latency period of the first open part entry (the entry of the animal with 
two forelimbs into the central platform), 2) number of line crossings in 
the open part (open arms + central platform area), 3) total time spent in 
the open part of plus-maze, 4) number of closed and open arm entries, 
and 5) ratio between open and closed arm entries. At the very beginning 
of the experiment an animal was placed into the centre of the plus-maze 
facing to the closed arm. Rats did clearly prefer the enclosed arms. Ah arm 
entry was counted only when all four limbs of the rat were within a given 
arm. Each animal was used in only one experiment The precaution was 
taken to control the possible daily fluctuations in the exploratory activity 
of animals. Therefore, the experiments were always performed in random­
ized order, i.e., the rats in groups were always used in parallel with singly 
housed rats. Caerulein (0.1-5 pg/kg s.c, Bachem, Bubendorf, Switzerland) 
was injected 15 min before the beginning of the plus-maze experiment 
Radioligand binding experiments. Rats (8 isolates and 8 animals 
kept in social groups) were decapitated and the brains were quickly dissect­
ed. Brain tissue was homogenized in 20 volumes of ice-cold Tris-HQ (pH 
7.4 at 4eC) using a PotterS glass-teflon homogenizer (1000 rpm, 12 
passes). The membranes were washed twice in the same buffer by centrifu-
gation and resuspension. For CCK-8 binding experiments the pellets were 
homogenized in HEPES buffer (10 mM HEPES; 130 mM Nad; 5 mM 
КО; 1 mM EDTA; pH 6.5 adjusted with 5 N NaOH) containing bovine 
serum albumin (0.5 m^ml). CCK-8 receptor labelling was carried out in 
the presence of 0.05-2.4 nM tritiated ligand, [propionyl-3H]propionylated-
CCK-8-sulphated ([^HjpCCK-8, specific activity 79 Ci/mmole, Amersham 
Radiochemicals) at room temperature in a total incubation volume of 0.5 
mL Caerulein (100 nM) was added to determine nonspecific binding. For 
10 
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benzodiazepine receptor labelling the pellets were homogenized in Tris-
HC1 buffer and the membrane preparations incubated in the presence of 
0.25-16 nM N-methyl-[3H)-flunitraizcpam (specific activity 84 G/mmole, 
Amersham Radiochemicals) at 4eC in a total volume of 0.5 ml in the 
presence or absence of unlabelled diazepam (10 цУА) to determine nonspe­
cific binding. Incubation was terminated after 120 min ((3H]pCCK-8 
binding) or 60 min Q3H]-flunitrazepam binding) by rapid filtration over 
Whatman GF/B filters using a Brandel Cell Harvester (M-24S). The filters 
were washed with 10 ml cold incubation buffer, dried and assayed for 
radioactivity by liquid scintillation spectrometry. The protein content was 
measured according to a modification of the Lowry procedure (Markwell 
et al. 1978). Saturation curves were analyzed using non-linear least squares 
regression (Leatherbarrow 1987). 
Statistics. Two-way analysis of variance followed by Duncan's 
multiple range test was used for evaluation of the behavioural data. 
Student's t-test for paired observations was used to determine statistical 
significance of the results obtained from the radioligand binding experi­
ments. 
Results 
The social isolation of rats for 7 days reduced nearly all the 
behavioural parameters registered in an elevated plus-maze (Figure 1, two-
way ANOVA, F| gg=27.02, P<0.01 line crossings; Fj gg=21.24, P<0.01 time 
spent in open part; Fj^g-15.84, 140.01 enclosed arm entries; Fj gg=7.50, 
P<0.05 open arm entries; all compared to the respective values o( the rats 
kept in groups of four). Latency of first open part entry was increased in 
isolated animals (two-way ANOVA, Fj gg=10.28, P< 0.01). The ratio be­
tween open and enclosed arm entries was not changed significantly, 
probably owing to the limited number of open arm entries made by 
control animals: 0.9 ± 0.3 entries during the observation time. 
The administration of caerulein produced statistically significant 
reduction of line crossings (Figure 1, two-way ANOVA Fj gg=3.54, P<0.05) 
and enclosed arm entries (two-way ANOVA F3>gg=2.83, P<0.05). The com­
parison of the action of caerulein upon the exploratory behaviour of 
single housed and group-housed rats revealed the difference only in the 
case of the time spent in open part (two-way ANOVA F^ gg=3.01, P<0.05). 
Accordingly, in single housed rats caerulein at lower doses (0.1 - 0.5 lig/kg) 
tended to increase time spent in exploration of open parts compared to 
that in rab kept in groups. 
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Figure 1. Effect of social isolation upon antiexploritory action of 
caerulein in rats. 
Pert A. Number of line crossings. Saline treated rats kept in groups 
made 16.1 ± 0.6 line crossings. , 
Pett B. Number of closed arm entries. Saline treated rats kept in groups 
did 5.7 ± 0.55 closed arm entries. 
Part C. Latency of first open part entry. This value of saline treated 
group-housed rats was 16 ± 2 «. 
Part D. Time spent in open part Saline treated group-housed animals 
spent 114 ± 11 * in open part 
Part EL Ratio between open and closed arm entries. This value of saline 
treated group-housed rats was 16 ± 5. 
Caerulein was injected 15 min before the beginning of the experiment 
* - P < 0.05 (Duncan's multiple range test after significant two-way 
ANOVA, comparedto saline treated group-housed animals). 
- P< 0.05; - P< 0.01 (compared to the respective values of group-
housed rats). 
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[^H]pCCK-8 binding sites in the frontal cortex (BmiJt) were increased 
in the isolated rats compared to rats in groups (P<0.05). No such a differ­
ence was seen in the other forebrain regions (mesolimbic area, striatum 
and hippocampus) (Table 1). 
On the contrary, the isolation of rats did not affect the parameters 
of [^H]-flunitrazepam binding in the rat frontal cortex. In rats kept in 
groups of four the dissociation constant of |^H)-flunitrazepam binding 
was 1.65 ± 0.22 nM and the apparent number of binding sites was 1096 
± 88 fmol/mg protein, whereas in isolates these values were 1.95 ± 0.29 nM 
and 1262 ± 94 fmol/mg protein, respectively. 
Table 1. Effect of rats' social isolation upon pH]pCCK-8 binding in 
the rat forebrain 
Brain structure Rats in groups Single rats 
Кн В
тят KH Bmar 
Cerebral cortex 
Mesolimbic area 
Striatum 
Hippocampus 
0.60±0.05 11.7 ±0.79 
0.61 ±0.04 12.5±0.73 
0.47Ю.03 12.4 ±0.73 
0.73±0.10 6.5±0.64 
0.71 ±0.03 15.0±1.28 
0.60±0.02 12.9±0.89 
0.39±0.03 13.1 ±0.62 . 
0.71±0.11 5.8±0.62 
Kj, dissociation constant (nM); 
Bmax, apparent number of binding sites (fmol/mg protein). 
Statistics: P < 0.05 as compared to grouped rats 
Discussion 
The isolation of rats immediately post-weaning has been shown to 
suppress the exploratory behaviour of animals in an elevated plus-maze 
(Wright et al. 1990). However, in our present study already the 7-day 
isolation of sexually mature rats markedly inhibited the exploratory 
activity of animals in the plus-maze test. Since it is well-known that 
various anxiogenic drugs inhibit the exploratory behaviour of rodents 
(Harro et al. 1988, 1989), we are tempting to conclude that the isolation 
of rats induced an anxiety-like state in these animals. In parallel binding 
studies, the number of [3H]pCCK-8 binding sites was elevated in the 
frontal cortex of isolated rats compared to the rats kept in groups. This 
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result could support the view that CCK-ergic mechanisms contribute to 
the development of anxious behaviour in the rat (Harro and Vasar 1991b). 
Since dopaminergic and serotonergic systems are also affected by 
social isolation (Blanc et al. 1980; J ones et al. 1988; Crespi et al. 1992), 
there may be important interactions between various neurotransmitter 
systems. This interplay could be related to the dense morphofunctional 
interaction of CCK-ergic and the major monoaminergic systems in the 
brain. The (»localization of dopamine with CCK in the mesencephalic 
neurons, innervating mainly the limbic and cortical regions, is widely 
accepted (Hökfelt et al. 1980). On the other hand, the intra-
cerebroventricular administration of CCK-4, a selective CCKg agonist, 
affected the metabolism of serotonin in several brain regions (Itoh et al. 
1988) and increases the density of serotonin-receptors in the cerebral 
cortex (Agnati et al. 1983). 
CCK has also a considerable functional interaction with GABA-ergic 
mechanisms in the cerebral cortex and hippocampus (Somogyi et al. 1984). 
However, no eventual changes in the parameters of benzodiazepine recep­
tors have been found (Morinan et al. 1992; the present study). Moreover, 
a benzodiazepine agonist diazepam is not able to block the anxiogenic-like 
effect of caerulein, an unselective agonist at ССКд/CCKg receptors, in the 
plus-maze test (Harro et al. 1990a; our unpublished data). This seems to 
indicate that GABA-ergic system is not involved in the isolation-induced 
anxiety in the rat 
It is noteworthy that the most, if not all, of CCK-8 binding sites in 
the frontal cortex belong to the CCKg receptor subtype (Hill et al. 1987). 
Various anxiogenic manipulations with rats have been demonstrated to 
cause the up-regulation of [3H]pCCK-8 binding sites in the frontal cortex. 
Indeed, the systemic administration of the anxiogenic compound FG 7142, 
an inverse agonist at benzodiazepine receptors, and the withdrawal of long-
term benzodiazepine treatment increased the number of CCKg receptors 
in the frontal cortex (Harro et al. 1990b, c). This finding was also support­
ed by the plus-maze selection study, where the animals having the low 
exploratory activity by nature have significantly higher density of CCKg 
receptors in the frontal cortex compared to their 'non-anxious* counter­
parts (Harro et al. 1990c). Now we found that also a social isolation of rats 
increased the number of CCKg receptors exclusively in the frontal cortex. 
These findings may have some significance for human anxiety, since CCK 
receptor density in the frontal cortex of suicide victims is also higher than 
in matched controls (Harro et al. 1992). 
The anti-exploratory effect of caerulein, the unselective agonist at 
ССКд/CCKg receptors, was not visible in the plus-maze test in the ani-
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mais isolated for 7 days. The lack of the effect of caerulein in the isolated 
rats could be explained by the above finding that the animals with the 
'anxiogenic-like' behaviour had a higher density of CCKg receptors com­
pared to behaviourally more active rats. It may be that in these "anxious* 
rats, an endogenous CCK alone is able to suppress nearly maximally the 
exploratory behaviour. Similar unresponsiveness of animals to the anti-
exploratory effect of caerulein has been established in mice after withdraw­
al of long-term diazepam treatment, when the baseline anxiety of animals 
was high (Harro et al, 1990a). 
A hypothesis of the importance of endogenous CCK and particularly 
the increased number of the cortical CCKg receptors in anxiety is further 
supported by a recent study where CI-988, a selective antagonist at CCKg 
receptors, blocked the behavioural signs after benzodiazepine withdrawal 
(Hughes et al. 1990). Since much lower doses of caerulein are needed to 
block the exploratory activity of rats after peripheral administration 
(Harro et al. 1990a; Vasar et al. 1992) if compared to the central applica­
tion of CCK agonist (Singh et al. 1990), it is doubtful that the peripherally 
administered caerulein really could interact with the CCKg receptors in 
the cerebral cortex. Rather, CCKg receptors in the nucleus of solitary tract 
could be the targets for the anxiogenic-like effect of CCK agonisb 
(Branchereau et al. 1992), assuming that there is a relation between the 
density of CCKg receptors in the cerebral cortex and the sensitivity of 
CCKg receptors in the brainstem structures. 
In conclusion, the isolation of sexually mature rats for 7 days induces 
in these animals the anxiety-like state. This behavioural change is associat­
ed with the increased number of CCKg receptors in the frontal cortex of 
rats without any effect on benzodiazepine receptors. 
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Abstract 
The ionic current mechanisms underlying ischemic arrhythmias have 
been the' subject of great interest and investigation. We studied cardiac 
myocytes treated with the ischemic metabolite lysophosphatidylcholine 
(LPC) using both the cell-attached and excised inside-out patch clamp 
technique at 22 oC In addition to previously recognized LPGinduced 
non-inactivating Na channels we have found that larger concentrations of 
LPC and/or more prolonged incubation time induces Na channels open­
ings at potentials negative to usual Na channel threshold, that could be 
described as complete removal of inactivation and shift in 
voltage-dependence of activation of Na channel. Both kinds of modified 
Na channels may play a role in development of cardiac cells depolarization 
during ischemia. At the other hand, they could be the important targets 
for antiarrhythmic drugs. 
Introduction 
Ischemia-induced depolarization (ID) of myocardial cells known as 
one of the major phenomena responsible for cardiac arrhythmias (12). The 
loss in resting potential results in inactivation of sodium channels, slow­
ing of excitation conduction, reentry circles formation and abnormal 
automaticity development. 
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At least two different mechanisms of depolarization thought to be 
involved in ID development First one is failure of regenerative 
repolarization and the appearance of new steady level of membrane poten­
tial (Vm) close to action potential (AP) plateau voltage level. Such phenom­
enon has been found in ischemic Purkinje fibers (22), in Purkinje fibers 
damaged by the isolational procedure (1) or treated with ischemic metabo­
lites (2). Second mechanism of ID is well-known gradual ID associated 
with extracellular К accumulation recognized in both in vivo and in vitro 
ischemia (see for review Reference 12). The electrophysiological mecha­
nisms of both kinds of ID are not completely known. 
Lysophosphatidylcholine (LPC), toxic metabolite of sarcolemmal 
phosphatidylcholine, has long been suspected to be one of the mediators 
of acute ischemic changes in heart (7). LPC induces electrophysiological 
alterations (including both types of ID) and arrhythmias which closely 
parallel those observed in early ischemia (7). We had previously shown that 
LPC decreases probability of Na channel opening and induces a slowing 
of Na channels inactivation (2, 4, 22). We report here that larger concen­
trations of LPC and/or more prolonged incubation time induces Na 
channels openings at potentials negative to usual Na channel threshold, 
that could be described as complete removal of inactivation and shift in 
voltage-dependence of activation of Na channel. Some of these data have 
been presented in abstract form (21), We will try also to discuss plausible 
role of LPCinduced alterations of Na channel gating in ID development 
Methods 
Channel recordings were made from enzymatically dispersed ventricu­
lar cells of adult rat heart isolated by a method similar to that described 
elsewhere (20). Single - channel currents were recorded using patch-clamp 
technique (9) in cell attached and inside-out configurations. LPC (Serva, 
9-13 uM) was applied to the inner side of inside-out patches. Some experi­
ments were made using the cells preincubated in LPCcontaining solution. 
Cell suspension was exposed to LPC (20 uM) in storage solution for 1 -
3 h before experiments were done. Storage solution contained (mM): Nad, 
135; KCl, 5.4; MgCl2, 1.2; CaQ2, 0.3; HEPES buffer, 5; glucose, 10; pH 
7.2. Solutions used in cell attached experiments: bath solution had the 
same composition as the storage solution, except the NaCl was replaced 
with KCl with the purpose to depolarize cells; pipette solution solution 
had a similar composition as the storage one but KCl was replaced by 
CsC!. In inside-out experiments bath solution contained (mM): CsF, 100; 
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KCl, 34; NaCl, 3.6; EGTA, 10; HEPES-KOH buffer 10; pH 7.2. The pipette 
solution had a similar composition as a pipette solution for cell attached 
experiments. Experiments were performed at room temperature 21 - 23oC 
Results 
Application of depolarizing pulse (Fig. 1A) from holding potential 
(Vh) of-120 mV to -20 mV (close to action potential plateau) results in 
simultaneous opening of Na channels at first few milliseconds. After that 
Na channels have been opened as well as non-opened channels become 
inactivated and don't open despite the maintained depolarization. Never­
theless, an extremely little number of Na channels openings could be 
observed at later times due 1) delayed first openings of some channels; 2) 
reopenings, i.e. second openings of channels once have been opened (16); 
3) burst-like openings of the channels operating in kinetic mode with 
modified gating (18). 
Application of LPC (9-13 uM) to inner side of inside-out patch 
markedly increases the probability of appearance of Na channels demon­
strated burst-like gating (Fig. IB). Frequency of bursts and burst length 
progressively increased with time and at 30-60 min of LPC application the 
bursts lasted up to end of 300- ms depolarizing pulse. Thus at that time 
clamping of membrane back to Vh rapidly cease any Na channel activity. 
Holding of membrane at more positive Vh of -60 mV resulted in complete 
elimination of both control and burst-like activity. We have concluded 
that short-term (up to lh) LPC exposure provoke Na channels to operate 
in mode with slower entrance in inactivation state. 
More prolonged LPC exposure (1-3 hours, exposed was cell suspen­
sion) resulted in appearance of completely non-inactivating sodium chan­
nels seems to operating in wide range of membrane potentials (-180 mV 
- +60 mV). Such channels activity was recognized in both cell attached 
(Fig. 2) and inside-out (not shown) patches from LPGpreincubated cells. 
In contrast to Ca-activating cation-unspecific channels described earlier (5), 
resting Na channels functioned in presence of 10 mmol/I EGTA from 
inside and have potential-dependent gating kinetics (Fig.2). Reversal 
potential for these channels interpolated from single-channel 
voltagecurrent relationship was close to Na equilibrium potential predicted 
by Nernst equation. 
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Discussion 
Because low doses of tctrodotoxin (TTX) shorten the plateau of AP 
and induce the slight but statistically significant hyperpolarization in 
cardiac Purkinje fibers without affecting the upstroke velocity, Coraboeuf 
with coworkers (6) suggesting that there are at least two sodium currents 
that are different from the one underlying AP upstroke. Further step in 
understanding the nature of sodium current taking part in AP plateau 
maintenance was made by Patlack and Ortiz (18) demonstrated that 
cardiac sodium channels in extremely small percent of sweeps could 
operate in burst-like mode. Respecting high density of sodium channels 
(especially in Purkinje fibers, Reference 8), despite low probability of 
burst-like behavior, the current through these channels might be substan­
tial and contributive in AP plateau maintenance. 
Marked increase in probability of burst-like channel activity found 
after short-term LPC application might induce imbalance between inward 
and outward ionic currents determining AP plateau formation resulting 
in progressive AP prolongation and, finally, in second stable voltage level 
development (2). Such loss of regenerative repolarization thought to be 
one of the prominent mechanisms of ischemic arrhythmogenesis (22). 
Preferential blockade of noninactivating Na channels by TTX (13) and 
lidocaine (10) could explain found property of these agents to normalize 
repolarization (11) and, possibly, beneficial antiarrhythmic properties of 
latter in early ischemia. 
Recently obtained data provide the basis for critical review of the 
proposed mechanisms of gradual ID development In particular, it has 
been shown that extracellular К accumulation is rather the result of 
enhanced passive К efflux than a decrease in cells К uptake by Na-K pump 
(15, 19). Na-K pump remains its functional activity, at least during the 
early ischemia (first 10 - 15 min). The hypothesis that decreased gK at RP 
level (for example, due LPC-induced decrease of inward rectifier potassium 
channels conductance, Reference 14) could induce gradual ID seems to be 
incorrect, because this actually opposes the well described increased net К 
efflux observed in ischemia. The alternative hypothesis that ID is a follow­
ing of increased К conductance (due to ATP-sensitive potassium channels 
partial activation, sec Reference 17) also seems to be controversial. The 
increased gK would cause the membrane potential to more accurately 
approximate the К equilibrium potential and at least initially would cause 
hyperpolarization. In addition, the driving force for К efflux would be 
reduced thus diminishing К accumulation. 
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Fig.1. Successive records of Na channels currents from insideout mem­
brane patch in control (A) and after 15 minutes of LPC (10 uM) 
application from inside (B). Holding potential was -120 mV and 100 
mV, 300 ms voltage clamp pulses were applied with the frequency of 1 
Hz. Leakage and capacities currents were partially subtracted only by 
analog circuitry. Downward deflection of current just after voltage pulse 
onset corresponds to simultaneous openings of Na channels. Note that 
after LPC treatment (B) one of the Na channels demonstrate burst-like 
activity up to about 200 ms after pulse onset. 
50 
m 
Fi|i. Na channels currents recorded in cell attached membrane patch 
from LPC-preincubated cardiomyocytes. LPC (20 uM) treatment lasted 
U h in storage solution (see Methods). Currents were elicited by 90 
mV, 200 ms voltage steps from holding potentials of -120 mV (A) or -60 
mV (B). Note that in both cases channels activity remained after mem­
brane was clamped back to holding potential (in contrast to less pro­
longed LPC exposure, Fig. 1). Note also a clear voltage dependence of 
resting Na channels gating kinetics. 
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This discrepancy might be overcame if initiation of additional small 
but permanent inward current close to RP voltage is postulated. Small 
depolarization inducing by this current could result in appropriate in­
crease in К current. Substantially decreased blood flow and increased net 
К efflux could provide unbalance in transmembrane К fluxes and increase 
in extracellular К concentration leading to further depolarization. 
The candidates to the role of such inward current are 1) 
cation-unspecific Ca-activated channels (5); 2) resting Na channels de­
scribed here. 
Defining the role of modified Na channels in ischemiainduced 
arrhythmogenesis may be useful for developing therapeutic strategies to 
deal with the leading cause of mortality from ischemic heart disease. 
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PLASMA MEMBRANE RECEPTORS 
AS TARGETS FOR CANCEROGENS 
(minireview) 
M. Zilmcr, E.Karclson 
Department of Medical Biochemistry, 
Tartu University 
This minireview highlights several facts which clearly indicate the 
crucial role of the plasma membrane and its components (especially 
receptors) in cancerogenesis. 
The first viewpoint: the plasma membrane, via its components, 
is intimately involved in the cell proliferation and canccrogene-
sis. 
Elucidation. It is widely accepted that several cancerogens interact 
with DNA to form its structural and functional changes. These alterations 
cause changes in gene products, which generation is followed by uncon­
trolled proliferation and cancer development [1, 9]. Besides, most current 
antitumor drugs (e.g. anthracyclines, platinum complexes, alkylating agents 
etc.) are directed also against DNA or/and nucleic acids biosynthesis. On 
the other hand, several cancerogens, including different oncogenes, cause 
some structural-functional alterations of the plasma membrane. It is 
noteworthy, that above-mentioned drugs cause these alterations already at 
therapeutic doses [13]. Consequently, the plasma membrane and its compo­
nents role in precise mechanism of several cancerogenic and 
anticancerogenic agents is really more important than has been appreciat­
ed. For example, it has been shown an important role of plasma mem­
brane receptors and associated signaling pathways in the molecular mecha­
nism of chemical cancerogenesis [3, 11]. Moreover, there is shown also a 
significant correlation between the degree of receptor binding and cancero­
genic activity among a series of cancerogens [4, 5). Additionally, the cancer 
initiation and promotion involve modulation of several receptor and 
second messenger systems. Among of them growth factor receptors and 
corresponding signaling pathways, including receptors for EGF (epidermal 
growth factor), PDGF (platelet derived growth factor), insulin-like growth 
factor; bombesin etc., are clear targets for certain cancerogenic agents (7, 
ll].It is also accepted, that this receptor family (characterised by the 
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tyrosine kinase activity) is involved in cell proliferative response via several 
intracellular events: phosphorylation of intracellular proteins, activation 
of phospholipase C, stimulation of inositolphosphatides breakdown, 
activation of proteinkinase C, elevation of free cytosolic Ca^+ etc. It is 
noteworthy, that somehow or other all these events are associated with 
structural-functional alterations of the plasma membrane. 
The second viewpoint: in fact, only manifold end repeated 
character of the influence of cancerogens on the plasma mem­
brane components underlay the development of cancer. 
Elucidation. It is conceivable, that repeated activation of growth 
factor receptors and/or associated pathways by the cancerogenic "agonists" 
(mitogens) leads by different molecular mechanisms to the activation of 
corresponding oncogenes and to the uncontrolled cell proliferation. It 
seems likely, that many cancerogens amplify proliferative response, caused 
by endogenous growth factor signals. For example, simultaneous exposi­
tion of pulmonary neuroendocrine (PNE) cells to different mitogens -
chronic hypooxygenation (or hyperoxygenation) and nicotine (or 
nitrosamines) induces neuroendocrine lung tumors[10]. On the other 
hand, cancerogenic "agonist" binding with its "specific" receptor can affects 
several other receptors and associated pathways, especially those of musca­
rinic and adienergic receptors as it is demonstrated in the case ot 
mcthapyrilenc [4]. It is important to consider that some cancerogens 
realize their modulatory effects only via intracellular messenger systems. 
Thus, phorbo! esters family can activate proteinkinase С (component of 
many growth factor signaling cascade) and therefore amplify the physiolog­
ical mitogenic response initiated at the receptor level [3]. At the same time 
seme chemical cancerogens (e.g. nitrosamines) can mimic such physiologi­
cal ligands as serotonin, catecholamines, acetylcholine and several peptide 
hormones and affect of cAMP-dependent protein kinase (I isozyme) which 
is actively proliferating enzyme in normal and cancerous tissues [8]. 
The third viewpoint: the role of the lipids in cancerogenesis 
and in сапсст therapy is more important than has been appre­
ciated. 
Elucidation. Many of plasma membrane essential components 
(several ionic pumps, receptors etc. ) are lipoproteins. Consequently, the 
lipid status of the plasma membrane regulates significantly the function­
ality of these systems (13 .etc.]. Besides, several growth factors, including 
PDGF. EGF. bombesin and thrombin, stimulate a phoshatidyl 
iz.ositol-4,S-bi?hospha« (PIP)) specific phospholipase С This is followed 
by generation of :nosito!-l,4.5-t?iphosphate (IPg) and diacylglycerol (DAG). 
It is noteworthy, that PIPj, iPj and DAG are lipids. In fact, lipid (1P3) 
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causes the release of Ca^+ in cell and lipid (DAG) activates protein kinase 
С and both these events are important mitogenic signals [1]. 
The platelet activating factor (PAF) is also lipid. Recently, by the cloning 
of the receptor cDNA from guineapig lung, the existence of a membrane 
receptor for PAF has been shown [6]. Evidently, this is the first 
lipidmediator receptor gene to be cloned and it belongs to the superfamily 
of G-protein-coupled membrane receptors (2, 15]. Synthetic analogues of 
PAF - ether lipids- are phospholipids analogues and they inhibit the 
crucial signal transduction enzymes: protein kinase С and phospholipase 
G As these ether lipids directed against the plasma membrane and do not 
affect DNA (15], such kind phospholipids analogues are a new class of 
antitumor agents which action mechanism realizes via an interference with 
plasma membrane components functions. 
Additionally, the precise action mechanism of the oncoproteins 
remains still unclear. However, some data allowed to suggest that the 
action of oncoprotein E5 is mediated via plasma membrane lipids or their 
products [12]. It is noteworthy, that lipids free radicals may play the role 
of certain second messengers in this pathway. 
We really hope, that consideration of these viewpoints is valuable for 
researches both in the field of receptors theory and in clinical elaboration 
of new antitumor agents for cancer therapy. 
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POSSIBLE MECHANISMS OF 
GALANIN NEUROTROPIC ACTIVITY 
E. Karclson, M. Zilmcr, J. Laasik 
Department of Bioorganic and Biological Chemistry, 
Tartu University 
Galanin, a 29 amino acid long C-terminally amidated peptide, is 
widely distributed in central and peripheral nervous system. Binding 
studies with '^-galanin have demonstrated the highest galanin receptor 
(GR) concentration in hippocampus and hypothalamus [9]. However, the 
precise action mechanism of galanin remains still unclear. The present 
study aims to characterize the GR-mediated membrane events (alterations 
of adenylatcyclase and Na-pump activities), triggered by this neuropeptide 
in different rat brain regions. 
Materials and methods 
For the adenylate activity determination male albino rats (weighing 
200-250 g) were killed by decapitation. Their brains were removed rapidly. 
From the precooled brains were isolated three regions: frontal cortex, 
hypothalamus and hippocampus. Immediately after that the brain regions 
were homogenized in 4 volumes of ice-cold 10 mM Tris-HQ (pH 7,4), 
homogenates were diluted 1:15 with mentioned buffer, mixed on ice for 
30 min and centrifuged for 6 min at 1600 g. Supernatants were discarded 
and pellets resuspended in ice-cold buffer PB, containing 30 mM Tris-HQ, 
1,5 mM theophylline, 8,25 mM MgCl2, 0.75 mM EGT A, 7,5 mM KCl, 100 
mM NaCl (pH 7.4) to get a protein concentration 0,5-1.0 mg/ml. Adenyl­
ate cyclase activity was measured by determining the formed cAMP and 
expressed as pmoles cAMP /min per mg of protein. For the assay of basal 
activity membrane proteins (final concentration 0.03-0.04 mg/ml) incubat­
ed in the reaction buffer, containing above-mentioned PB, 0,1 mg/ml 
bacitracin, 0.05% human serum albumin, 0.01 mM GTP, 1,0 mM ATP and 
an ATP-regenerating system. Galanin (10 "*M) effect was assessed in the 
same incubation mixture. Assay of forskoline (10'^M) stimulated adenylate 
cyclase was introduced for more exact determine of galanin effect. Enzyme 
reaction was initiated by the addiuon of ATP and terminated after a 15 
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min incubation at 30°C by adding 100 mM EDTA and boiling of samples 
for 3 min in a water bath. Protein precipitate was removed by centrifuga-
tion at 600g. Aliquots of supernatant were used for the cAMP measure­
ments by [2]. Bovine adrenal glands were used as the source of high 
specific cAMP-binding protein. 
Protein determination was performed according to [6] using bovine 
serum albumin as a standard. 
Basal adenylate cyclase level in cortex, hypothalamus and hippocam­
pus was respectively 86±3, 111±3 and 77±7 pmol cAMP/min per mg 
protein. 
The enzyme preparations (membrane fragments) of the Na,K-ATPase 
from different rat brain areas were isolated as previously described [4]. The 
enzyme activity estimation, the treatment with phospholipase A2 (PLA2) 
and SDS were performed according to procedure described earlier (5]. The 
determination of the phospholipids (PL) and cholesterol (CH) were per­
formed as described in literature [5]. 
Student's t-test for paired observations was used to determine statisti­
cal significance of experimental results. 
Results 
As shown in table 1 the basal adenylatcyclase activity of hypothala­
mus and hippocampus was poorly activated by galanin: 23±7% and 13±3% 
respectively. Although the enzyme from frontal cortex was also activated, 
this effect was not statistically significant. 
Unlike to basal adenylate cyclase the forskolin-stimulabed enzyme was 
significantly inhibited by this peptide (table 1). The inhibition was more 
remarkable in the case of hypothalamus (59%) and hippocampus (50 %). 
Small inhibition was also established in frontal cortex (11%). 
In connection with mentioned above is noteworthy, that gala- nin 
inhibits the rat brain Na-pump . As is shown in table 2 this inhibition 
was incomplete. Besides, the inhibitory effects were different in various 
brain areas and there was a definite correlation between the content of PL 
and CH in various brain areas and the inhbition degree. 
59 
Tabic 1. Galanin (10"^M) effect on the basal and forskolin-stimulated 
adenylate cyclase activities in rat brain frontal cortex, hypothalamus and 
hippocampus. 
Brain region 
Adenylate cyclase activity 
(% of basal value) 
Basal 
Basal + 
Galanin 
Forskolin-
stimulated 
Forskolin-
stimulated 
+ Galanin 
Frontal cortex 100±3 112±5 409±3* 363±3* 
Hypothalamus 100±2 11313- 408±3* 167±6* 
Hippocampus 100±9 123±7* 397±2* 196±3* 
The data are means ± S.E.M. from 4-8 experiments and expressed as 
percentage of the respective basal (control) values (100 %). 
* - statistically significant (P< 0.01) alterations of adenylate cyclase 
activity. 
Table 2. The inhibitory effect (%) of the galanin (Ю-3 M) on the activi­
ty of the rat brain Na,K-ATPase and the content of PL (gmol P/mg 
protein) and CH (arbitrary units) in the enzyme preparations. 
Galanin* +PLA) +SDS PL CH 
Frontal cortex 40±8 8 ±2 5±2 1.04 11.8 
Substantia 44±7 3±2 - 1.17 13.0 
nigra 
Hippocampus 54±7 5±2 3±2 1.05 9.3 
Striatum 37±6 • - - 0.92 7.6 
Nucleus 19±3 . . 0.69 7.0 
accumbens 
* all galanin's effects were statistically significant (140.05) 
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Discussion 
The low activating effect of galanin on basal adenylate cyclase activity 
in hypothalamus and hippocampus may refer to a direct binding of the 
peptide with its receptors, coupled to the cAMP production system. In 
fact, it is shown that GR high concentration is namely in hypothalamus 
and hippocampus [6,9]. Additionally, galanin binding with other receptors 
of brain is evidently unlikely, because this peptide is not a member of 
neuropeptides family known nowadays [8]. However, some data show the 
existence of negative coupling-mechanism (via Gj) between GR and adenyl­
ate cyclase in several organs and tissues [1,6]. One explanation of this 
phenomenon is following: a tissue- and/or species-specific cofactor which 
is needed for inhibition) of adenylate cyclase by galanin in vivo, is absent 
in our experiments (disappears during membrane preparation or misses 
in the enzyme assay medium). 
This study shows inhibitory effect of galanin on the 
forskolin-stimulated brain adenylate cyclase similar to that obtained in 
several other observations [1,6]. Evidently, such effect is due to the confor­
mational changes of the oligomeric enzyme after the treatment by this 
cardioactive diterpene. Obviously, conformation state of adenylate cyclase, 
induced via forskolin binding (with the enzyme catalytic unit), supports 
the inclusion of Gj in the mechanism of GR adenylate cyclase interaction. 
In many aspects, our observation suggests that cAMP production 
system as well as other functionally active membrane systems (ion-channels 
and ion-pumps) in plasma membrane are important transmembrane 
signaling pathways for galanin's effect in various brain regions. At the 
same time, the regulative action of bioactive ligands realizes evidently in 
situ via several mechanisms. It means that the regulative effects of such 
ligands may be mediated via plasma membrane lipids and their active 
products. For example, it is suggested recently, that in suitable lipid 
medium of the plasma membrane the exact, strong and effective binding 
of the ligands is guaranteed [ 3 ]. The lipoproteinous nature of the plasma 
membrane active systems mentioned above and incompleteness galanin's 
effects on them refer to possibility that the lipid-protein interactions may 
play a definite role in regulative mechanism of this peptide. Our such 
suggestion is supported also by following facts: 1) the inhibitory effect of 
galanin disappears practically after the treatment with delipidative agents 
- PLA.. and SDS (table 2), 2) the lack of ATP protective effects against the 
influence of galanin or PGEjflipohilic modificator of brain Na-pump) on 
the brain NaJC-ATPase [5], 3) the lack of competijion between the galanin 
and the regulativ»; ions (sodium and potassium) in the case of brain 
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NaJK-ATPase [5], 4) a definite correlation between the effect of galanin and 
the Na,K-ATPase preparations lipid status (table 1 and [5]). 
This study shows small regulative effects of galanin on brain basal 
adenylate cyclase and Na,K-ATPase activities, which is in agreement with 
the other investigations. Futher studies are required to clarify whether 
molecular mechanism of this neuropeptide is in situ coupled to other 
membraneous and/or intracellular transduction systems (e.g. lipids). 
Acknowledgements: We are greatly indebted to our colleague dr. 
Ylo Langel (Department of Biochemistry Arrhenius Laboratory University 
of Stockholm, chairman dr. T. Bartfai) for providing us galanin and other 
reactives. 
References 
1. Amiranoff В., Lori net A.M., Laburthc M. A clonal rat pancreatic о cell 
line (Rinl4B) expresses a high number of galanin receptors negatively coupled to 
a pertussis-toxin-sensitive cAMP-production pathway// Eur. J. Biochem. - 1991,-
vol. 195. - P. 459463. 
2. Brown B.L, Ekins R.P„ Albino J.D.M. Saturation assay for cyclic AMP 
using endogenous binding protein // Adv. in Cyclic Nucleotide Research - 1972. 
- vol. 2. - P. 2540. 
3. Cossori P, Lankford S.P, Bonifacino J.C, Klausner R.D. Membrane 
protein association by potential intramembrane charge pairs.// Nature -1991.-vol. 
351. - P. 414416. 
4. Kartlson L, Zilmcr Mn Tähepõld L Prostaglandin Ej as a 
lipophilic modulator of Na-pump. // Quest. Med. Chem. - 1985 -
vol. 31. - P.'84-87 (in Russian). 
5. Laasik J., Sillard R., Langd Y., Zilmcr M. The lipid-protein interactions 
as an additional mechanism of Na-pump regulation 
// Acta Physiol. Scand. (Supplement). - 1992,- P. 64-66. 
6. Land T„ Langd Y., Fisonc G., Bcdccs K. Bartfai T. Assay for galanin 
receptor // Methods in Neurosciences - 1991. - vol. 5. - P. 225-234. 
7. Lowiy O.H., Roscnbrough N.J., Farr A.L, Randall R.J. Protein measure­
ment with the Folin phenol reagent // J. Biol. Chem. - 1951. - vol. 193. - P. 
265-275. 
8. Tatemoto Kn Rökaeus A., Jornvall H, McDonald T.J., Mutt V. Galanin 
- a novel biologically active peptide from porcine intestine. // FEBS Lett - 1983,-
vol. 164. - P. 124-128. 
9. Skofitsch G-, Sills M-,Jacobowitz D.M. Autoradiographic distribution of 
125J-galanin binding sites in the rat central nervous system. // Peptides. - 1986.- vol. 
7 . -
P. 1029-1042. 
62 
FREQUENCY OF IMPAIRED HYDROXYLATION OF 
MEPHENYTOIN AND DEBRISOQUINE 
IN AN ESTONIAN POPULATION 
RA Kiivct1, J.O. Svensson2, L. Bertilsson2, F. Sjöqvist2 
j Department of Pharmacology, Tartu University 
^Department of Clinical Pharmacology, Karolinska Institute, 
Huddinge University Hospital 
Abstract 
Debrisoquine and S-mephcnytoin hydroxylation polymorphisms were 
studied in 156 unrelated native Estonians. The hydroxylation phenotypes 
were assessed by coadministration of mephenytoin with debrisoquine or 
dextromethorphan. The frequency of the poor metaboliser phenotype of 
debrisoquine/dextromethorphan was 4.5 % (95 % confidence interval 1.2 -
7.8 %), and that of mephenytoin was 3.9 % (95 % confidence interval 0.9 
- 6.9 %) among Estonians, which is very similar to that in other Caucasian 
populations. 
Introduction 
Interest in polymorphic drug metabolism has grown rapidly over the 
last 15 years. Since the description of the genetic polymorphisms of 
debrisoquine/sparteine [5] and S-mephenytoin (20), several important 
interindividual differences in drug responsiveness can be explained by 
polymorphic drug oxidation [5,20]. Pronounced interethnic differences 
between Caucasian and Oriental populations in the hydroxylation 
polymorphisms have been demonstrated [12]. 
It is considered that most European Caucasians have evolved from a 
Caucasoid descendant genetically distinct from the progenitors of Oriental 
populations [4]. Nevertheless, in this worldwide reconstruction of human 
evoluUon, some European populations (Basques, Finns, Hungarians and 
Estonians) seem to differ both genetically and linguistically from the 
others. Previous studies of polymorphic drug metabolism among Hungari­
ans [17] and Finns [2,16] were limited to debrisoquine hydroxylation 
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phcnotyplng and did not reveal significant differences from the average 
European population [1]. 
It has been shown that coadministration of debrisoquine and 
mephenytoin [13], or dextromethorphan and mephenytoin [8], docs not 
interfere with the phenotyping test results. Also, the probe drugs 
debrisoquine and dextromethorphan [9,14] identify the same activity of the 
debrisoquine hydroxylase (cytochrome P4502D6). Therefore, a combination 
approach was used to study prevalence of hydroxylation polymorphisms 
in a previously uncharacterized population of Estonians. 
Methods 
A total of 156 unrelated Estonians (55 men and 101 women, age 20 
to 31 years) were recruited from medical students of the Tartu University. 
The study group consisted of Caucasian Estonians of at least second 
generation living in Estonia. The subjects were interviewed and considered 
to be in good health, and they participated in the study after giving oral 
and written informed consent Subjects had not experienced any recent 
ilness, and were not taking any medication, except some had taken antibi­
otics or acetylsalicylic acid. 
After emptying his or her bladder at bedtime, each subject took a 10 
mg tablet of debrisoquine (Dedinax^, Hoffman-LaRoche; 78 subjects) or 
30 mg dextromethorphan in 15 ml syrup (Tussidyl , Tika; 78 subjects) 
together with a 100 mg tablet of racemic mephenytoin (Mesantoin®, 
Sandoz; all subjects). Urine was collected for 8 h, the total volume record­
ed and 10 ml stdred at -20° С until analyzed in Huddinge, Sweden. 
The mephenytoin S/R ratio in urine was determined by chiral gas 
chromatography according to [18] and modified by us [13]. In urine 
samples in which R-mephenytoin, but not S-mephenytoin could be detect­
ed, the S/R ratio was defined as the lower level of detection (0.05). The 
mephenytoin poor metaboliser (PM) phenotype was confirmed by acidifi­
cation procedure according to [19], and a subject was assigned a PM 
phenotype in case acidification did not change the urinary S/R ratio. 
Debrisoquine (DEB) and 4-hydroxydebrisoquine (4HDEB) in urine 
were analysed by the gas chromatographic method by [11]. The metabolic 
ratio was calculated by dividing the molar concentrations сf DEB and 
4HDEB. 
The concentrations of dextromethorphan (DXM) and dextrorphan 
(DO) in urine were determined by high performance liquid chromatogra­
phy (HPLC) after hydrolysis of glucuronidated DO. Hydrolysis; 0.5 ml of 
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urine was mixed with 100 pi of internal standard (640 pg disopyramid 
phosphate in 10 mM hydrochloric acid), 10 pi of ß-glucuronidase from 
Helix Pomatia type H-2 (Sigma), and 1.0 ml of 0.1 M sodium acetate 
buffer pH 5.0. The mixture was incubated in a shaking waterbath for 16 
h. Extraction: the incubated sample was mixed with 2.0 ml of 0.5 M 
ammonium sulphate pH 9.3 (adjusted with ammonia), and extracted for 
10 min with 5.0 ml of diisopropyl ether. Four ml of the organic phase was 
then extracted on a whirlmixer for 10 s with 200 pi of 50 mM phosphoric 
acid. HPLC : 20 pi of the phosphoric acid phase was injected onto a 10 
cm reversed phase column with 4.6 mm inner diameter, containing 3 pm 
Spherisorb Phenyl (Phase Sep, Dessida, UK). The eluent was a 10 mM 
potassium dihydrogenphosphate buffer pH 3.0 (adjusted with phosphoric 
acid) containing 25 % of acetonitrile. The flow-rate was 1.5 ml/min. 
Ultraviolet detection was carried out at a wavelength of 210 nm. Retention 
times were 2.6 min for DO, 4.2 min for disopyramid (internal standard), 
and 6.5 min for DXM. Standard curves were obtained by analysis of urine 
spiked with up to 4.0 pM of DXM, and up to 80 pM of DO. Peak heights 
were measured. The standard curves were linear with correlation coeffi­
cients of >0,998 (six points). The lower limits of detection were about 0.05 
pM for both DMX and DO. The metabolic ratio was calculated by divid­
ing the molar concentrations of DXM and DO. 
Two-tailed Students t-test was used for statistical analysis of group 
parameters. Conventional statistical procedures were applied to calculate 
standard deviatons and 95 % confidence intervals [7] for the prevalence of 
the two drug hydroxylation phenotypes. 
Results 
Six of the 156 investigated Estonians (3.9%, 95% confidence interval 
0.9 - 6.9%) had a mephenytoin S/R ratio ranging 0.93 - 1,44, indicating 
that they were PM of S-mephenytoin (Table 1 & Fig. 1). Of these, 3 were 
available to be retested with mephenytoin, and the second night urine (24 -
32 h) was collected. The S/R ratios 0.94 - 1.03 in this fraction confirmed 
that they were PM. The 0-8 h urines from the other 3 potential PM were 
acidified without any change in S/R ratio confirming that they also were 
PM. 
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Number of 
subjects 
0.1 o.s 1 1.5 
Mephenytoin S/R ratios in 156 subjects 
Number of 
subjects 
0.1 1 io loo 
Debrisoquine metabolic ratios In 78 subjects 
20 
Number of 
subjects 
0.001 0.01 0.1 1 10 
Dextromethorphan metabolic ratloe In 78 subjects 
Figure 1. The frequency distribution of the urinary mephenytoin S/R 
ratio and metabolic ratios of debrisoquine and dextromethorphan in 
156 Estonians. The filled columns represent poor metabolisers. 
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Table 1. Phenotypic traits of EMs and PMs of mephenytoin 
and debrisoquine/dextromethorphan in 156 unrelated subjects. 
The median and range are given and the results of urinary 
recovery of the study drugs are expressed as percentage of dose. 
EM PM 
Mephenytoin 
Nr of subjects 150 6 
S/R ratio of mephenytoin 0.17 1.0 
(0.05-0.78) (0.93-1.44) 
Debrisoquine 
Nr of subjects 74 4 
Metabolic ratio DEB/4HDEB 0.61 41.1 
(0.08-6.5) (28-50) 
Urinary recovery of DEB 9.4 42 
(1.243) (2745) 
Urinary recovery of 4HDEB 14 1.0 
(3.4-52) (0.06-1.6) 
Total recovery of DEB + 4HDEB 23 43 
(6.1-71) (2846) 
Dextromethorphan 
Nr of subjects 75 3 
Metabolic ratio DXM/DO 0.004 4.2 
(0.001- (2.8-5.7) 
0.17) 
Urinary recovery of DXM 0.28 4.5 
(0.001-3.5) (2.6-6.7) 
Urinary recovery of DO 22 1.0 
(5.7-75) (0.9-1.2) 
Total recovery of DXM + DO 23 5.0 
(5.7-76) (3.5-7.9) 
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Using the antimodes of metabolic ratios 12.6 for debrisoquine [3,6] 
and 0.3 for dextromethorphan [14], 4 of the 78 Estonians were PM of 
debrisoquine and 3 of 78 were PM of dextromethorphan (Table 1 & Fig. 
1). Thus 4.5% (95% confidence interval 1.2 - 7.8%) were PM of 
debrisoquine/dextromethorphan. The antimodes used here seem to apply 
also for this population. The total recovery of parent drug plus metabolite 
was higher in PM (median 43%), than in EM (23%; p - 0.01) of 
debrisoquine and the opposite for dextromethorphan (median 5% in PM 
and 23% in EM; p - 0.005). 
None of the subjects were PM of both debrisoqui ne/dextromethor­
phan and S-mephenytoin. 
Discussion 
The finding that 3.9 % of our subjects were PM of mephenytoin and 
4.5 % were PM of debrisoquine/dextromethorphan is in agreement with 
the average prevalence of these phenotypes in other European populations 
11]. 
While the distinction of individual phenotypes is reflected by a more 
marked difference in the urinary mephenytoin S/R ratio, when using later 
or longer urine collection times [3,13], this advantage must be weighed 
with the practical realities in an outpatient setting. Therefore, in our study 
we chose to later retest 3 potential PM and a later urine sample (24 - 32 
h) confirmed the phenotype. Three other potential PM were not available 
for retesting and we therefore used acidification to confirm the phenotype. 
Our group has previously shown, that acidification of the 0 - 8 h urine 
samples from 30 EM of S-mephenytoin increased the S/R ratio 8 - 127 
fold, while there was no change in the urine samples of 12 PM (Tybriug 
& Bertilsson, to be published). 
The total recoveries of DXM plus DO in our study is somewhat 
lower than those found previously [14]. The reason for this is not clear, 
but it is not likely to be the result of incomplete urine collection, as the 
recoveries of DEB plus 4HDEB are similar [15] or even higher [12], than 
the values reported in other Caucasian populations. 
The greater total recovery in urine the administered dose of DEB in 
PM subjects is due to a greater excretion of DEB. Despite the small sample 
size, this difference does not seem to be a chance finding, as it has been 
reported earlier in a large population [15]. It seems plausible, th.it in EM 
subjects of DEB, the debrisoquine hydroxylase forms more of ihe other 
metasbolit« parallel to 4HDEB. Such metabolites are usually mot roca-
sured, but have been found to account for 3 to 14% of the dose by Idle 
et al. in a small study population [10]. 
The importance of the hydroxylation polymorphism is not only 
academic. It may result in clinically important consequenses, as the metab­
olism of several groups of drug appears to cosegregate with the 
debrisoquine and mephenytoin hydroxylation trait [5,20]. This study has 
shown, that Estonians are not more prone to the possible diverse clinical 
effects of the drugs metabolised by polymorphic hydroxylation, than other 
European Caucasians. 
References 
1. Alvan G4 Bcchtel P, Iselius L, Gundcrt-Rcmy U. Hydroxylation 
polymorphisms of debrisoquine and mephenytoin in European populations // Eur. 
J. Clin. Pharmacol. - 1990.1 Vol. 39. - P. 533-537. 
2. Arvcla P, Kirjirint* M, KirjerinU M, Kirki Nn Pclkoncn O. Poly­
morphism of debrisoquine hydroxylation among Finns and Lapps // Br. J. Clin. 
Pharmacol. - 1988. - Vol. 26. - P. 601- 603. 
3. Bcrtilsson L, Lou Y.Q, Du Y.L, Liu У-, Kuang T.Y., Uao X.M., Weng 
K.Y, Rcviriego Jn Iselius L, Sjõqvist F. Pronounced differences between native 
Chinese and Swedish populations in the polymorphic hydroxylations of 
debrisoquine and S-mephenytoin // Clin. Pharmacol. Ther. - 1992. - Vol. 51. - P. 
388-397. 
4. Cevslli-Sforza LL, Piazza A., Mcnozzi P, Mountain J. Reconstruction 
of human evolution: Bringing together genetic, archeological, and linguistic data. 
// Proc. Natl. Acad. Sei. USA - 1988. - Vol. 85. - P. 6002-6006. 
5. Eichdbaum M-, Gross A S. The genetic polymorphism of 
debrisoquint/spirteine metabolism - clinical aspects I I Pharmacol. Ther. - 1990. -
Vol. 46. - P. 377-394. 
6. Evans D-A.P., Mahgoub An Sloan T.P, Idle J.R4 Smith R.L A family 
and population study of genetic polymorphism of debrisoquine oxidation in a 
white British population // J. Med. Genet. - 1980. - Vol. 17. - P. 102-105. 
7. Gardner M J-, Ahman D.G. Confidence intervals rather than P values: 
Estimation rather than hypothesis testing // Br. Med. J. - 1986. - Vol. 292. - P. 746-
750. 
8. Guttendorf R.J4 Britto Мч Blouin RA, Foster T.S., John W, Pittman 
KAn Wcdlund P.J. Rapid screening for polymorphisms in dextromethorphan and 
mephenytoin metabolism // Br. J. Clin. Pharmacol. - 1990. - Vol. 29. - P. 373-380. 
9. Hcnihorn  . ., Benitcz J, Avram M.J-, Martinez C, LLcrena A, 
Cobalcda J., Krejcie I .C-, Gibbons R.D. Assessment of the debrisoquine and 
dextromethorphan phenotyping tests by gaussian mixture distributions analysis // 
Clin. Pharmacol. Ther. - 1989. - Vol. 45. - P. 328-333. 
69 
10. IdlcJ.R, Mahgoub A, Angclo M.M, Dring LG, Lancesler R, Smith 
R.L The metabolism of [14C]-debrisoquine in man // Br. J. Clin. Pharmacol. -
1979. - Vol. 7. - P. 257 266. 
11. Lcnnerd M-S., Silas J.H-, Smith A.J, Tucker G.T. Determination of 
debrisoquine and its 4-hydroxymetabolite in biological fluids by gas chromatogra­
phy with flame-ionization and nitrogen-selective detection // J. Chromatogr. - 1977. 
-Vol. 133. - P. 161-168. 
12. Nekamure K, Goto F, Ray A, McAllister C.B, Jecqz E, Wilkinson 
G.R, Branch RA. Interethnic differences in genetic polymorphism of debrisoquine 
and mephenytoin hydroxylation between Japanese and Caucasian populations // 
Clin. Pharmacol. Ther. - 1985. - Vol. 38. - P. 402408. 
13. Sanz E.J, Villen T, Alm C, Bcrtilsson L S-mephenytoin hydroxylation 
phenotypes in a Swedish population determined after coadministration with 
debrisoquine // Clin. Pharmacol. Ther. - 1989. - Vol. 45. - P. 495499. 
14. Schmid B, Bircher J, Preisigg R, Kfipfcr A. Polymorphic 
dextromethorphan metabolism: Co-segregation of oxidative O- demethylation with 
debrisoquine hydroxylation // Clin. Pharmacol. Ther. - 1985. - Vol. 38.- P. 618-624. 
15. Steiner E, Bcrtilsson L, Sewc J, Bertling I, Sjöqvist F. Polymorphic 
debrisoquine hydroxylation in 757 Swedish subjects // Clin. Pharmacol. Ther. -
1988. - Vol. 44. - P. 431435. 
16. Syvilihti E.K.G, Lindbcrg R, Kellio J, De Vocht M. Inhibitory effects 
of neuroleptics on debrisoquine oxidation in man // Br. J. Clin. Pharmacol. - 1986. 
- Vol. 22. - P. 89-92. • 
17. Szõredy I, Santa A. Drug hydroxylator phenotype in Hungary // Eur. 
J. Clin. Pharmacol. - 1987. - Vol. 32. - P. 325. 
18. Wcdlund P.J, Swectmen B.J, McAllister C.B, Branch RA, Wilkinson 
G.R. Direct enantiomeric resolution of mephenytoin and its N-demethylated 
metabolite in plasma and blood using chiral capillary gas chromatography // J. 
Chromatogr. - 1984. - Vol. 307. - P. 121-127. 
19. Wcdlund P.J, Swectmen B.J, Wilkinson G.R, Branch RA. Pharma-
cogenetic association between the formation of 
4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man // Drug 
Metabol. Diposit. - 1987. - Vol. 15. - P. 277- 279. 
20. Wilkinson G.R, Guengcrich F.P, Branch RA. Genetic polymorphism 
of S-mephenytoin hydroxylation // Pharmacol. Ther. - 1989. - Vol. 43. - P. 53-76. 
70 
THE EFFECT OF VARIOUS ANXIOLYTIC/SEDATWE 
DRUGS ON THE LOCOMOTOR ACTIVITY 
OF SLEEP-DEPRIVED MICE. 
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Abstract 
In the present investigation, the effect of sleep deprivation 
(SD) on the locomotor activity of mice has been studied. The effect of 
benzodiazepine (BDZ) receptor agonist diazepam, BDZ receptor antagonist 
flumazenil, BDZ receptor inverse agonist RO 15-4513 as well as non-
benzodiazepine type anxiolytic/sedative drugs buspirone and baclofen on 
SD-induced changes in the locomotor activity of mice have been also 
studied. 
SD for 24 hours using the platform technique caused significant 
increase in the locomotor activity. 
Administration of diazepam (0.25 and 0.5 mg/kg), flumazenil (5 and 
10 m&/kg), buspirone (2, 4 and 8 mg/kg) and baclofen (1 mg/kg) excerted 
significantly more pronounced inhibitory action on the locomotor activity 
of SD mice in comparison to control. These data suggest that SD induced 
a sensitisation of mice to the sedative effects of anxiolytic/sedative drugs. 
A possible involvement of benzodiazepine receptors in this phenomenon 
is discussed. 
Introduction 
Sleep deprivation ( SD ) produces in laboratory animals several 
behavioural changes which are reflected by an increased aggressiveness (21 
), motor activity ( 2,3,16,17,20,33,45 ), sexual behaviour ( 31 ), anxiety ( 
19,46 ) and susceptibility to seizures ( 8,34,42,43,44 ). 
The most widely used technique for SD is platform technique which 
consists of keeping the animals en a small platform surrounded by water. 
The platform technique involves besides its specific action on sleep 
several other factors of stress such as isolation , immobilization , falling 
into the water and soaking ( 16,17 ) which produce an heavy stress in 
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laboratory animals ( 26,27 ). This experimental model must therefore be 
considered as a stress model of which SD is one factor ( 16 ). In connec­
tion with that there has been much discussion about the use of platform 
technique, in particular about the high level of non specific stress ( 
7,22,26,32 ). A peculiar feature of this model is that following the period 
of SD the animal does not fall asleep as could be expected but shows a 
constant period of wakefulness. 
The effects of many drugs known to interfere with central nervous 
system are different in sleep deprived animals to compare with control 
animals. Several studies have demonstrated that SD rats show an augment­
ed response to dopaminergic agents as indicated by an intensification of 
agrressiveness, stereotypy and rearing induced by apomorphine 
(4,5,6,9,10,11,38,39,40,41). Some works (16,17) claim that excitement which 
immediately follows SD is related mainly to the hyperactivity of 
dopaminergic systems, especially D1 receptors. 
There is evidence that acetylcholine, norepinefrine, opioids, 5-hy-
droxytryptamine and other neurotreancmitters are involved in the 
behavioural changes induced by SD (36,16,17,29,35,36, 25,30). 
There are fewer data about the influence of drugs acting at the 
benzodiazepine receptor on the behavioural changes induced by SD. In 
some studies neither diazepam nor the benzodiazepine receptor antagonist 
flumazenil (RO 15-1788) showed different action in SD animals as com­
pared to the controls (16). However, our previous studies revealed a 
decrease in GABA-stimulated chloride uptake by synaptoneurosomes 
prepared from the cortex of SD mice ( ). These observations suggest that 
some changes might occur in GABA-benzodiazepine-barbiturate complex 
might be involved in SD animals. 
Therefore we decided to study the effects of diazepam, BDZ receptor 
antagonist flumazenil ( RO 15-1788 ) and BDZ receptor partial inverse 
agonist RO 15-4513 on the changes in the locomotor activity of mice 
caused by sleep deprivation. In addition to this, the effect of 5-НТ|д 
receptor agonist buspirone and GABAg receptor agonist baclogfen were 
also studied. 
Materials and methods 
Animals-Male albino mice, weighting 25-30g were used throughout 
the study. Mice were maintained at 20±2 С with water and food ad libi­
tum. All experiments were carried out between 12 a.m. and 2 p.m. 
Sleep deprivation. Mice were deprived of sleep using the platform 
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technique. Mice were kept on platform ( d=3cm ) surrounded by water for 
24 hours, and were removed from the platform straight before the mea­
surement of locomotor activity. 
When drug or saline injections were carried out mice were returned 
to the platform before measurements. 
The measurement of locomotor activity. Locomotor activity 
was measured in actometer which consisted of individual cages: 
a cylinder with an inner diameter of 40 cm and 2 photocells located in the 
walls. Locomotor activity was measured during 60 minutes. Counts were 
registered after every 15 minutes. 
Drugs: The following drugs were used: diazepam, flumazenil ( RO 
15-1788 ), RO 15-4513 (Hoffman-LaRoche, Switzerland) , buspirone and 
baclofen (Ciba Geigy, Basle, Switzerland). All drugs were suspended in 
saline with a drop of Tween-80. The volume injected was adjusted with 
sahne to 0.1 ml/10 g body weght All drugs except RO 15-4513 were 
injected intraperitoneally (i.p.) 30 min prior to test. RO 154513 was 
injected i.p. 5 min prior to experiment 
Statistical analysis 
All data were analyzed using one-way analysis of variance Anova. 
Further statistical analysis was made by Student's t-test 
Results 
The effect of sleep deprivation on the locomotor activity of mice is 
shown in the Table 1. 
SD caused significant rise in the locomotor activity of mice which 
lasted about 60 minutes. 
In the low dose (0.25 mg/kg) diazepam did change locomotor activity 
neither in the control group nor in the SD animals (Table 2). 
The higher dose of diazepam (0.5 mg/kg) inhibited locomotor activity 
in both: control and SD mice. However, the inhibitory effect of diazepam 
was more pronounced in SD animals. BDZ receptor agonist flumazenil 
and BDZ receptor inverse agonist Ro 154513 in the doses used did not 
not affect locomotor activity of control animals. However, when 
flumazenil and Ro 154513 were administrered to SD mise these drugs 
significantly inhibited locomotor activity (Table 3 and 4). 
Similar inhibitory effect on locomotor activity in SD mice but noty in 
control was observed after administration of buspirone and baclofen 
(Table 5 and 6). 
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Table 1. The effect of sleep deprivation ( SD) on the locomotor activity 
of mice. Locomotor activity was measured in actometer during 60 
minutes. The number of counts was registered after every 15 minutes. 
The data are mean values ± SEM. The number of animals was 13 in the 
control group and 10 in SD group. *P<0.05; **P<0.01 
GROUP C O U N T S  
0-15 MINUTES CONTROL 
SLEEP DEPRIVATION 
133.4121.5 
353.5161.1** 
15-30 MINUTES CONTROL 
SLEEP DEPRIVATION 
112.3122.9 
272.4152.0* 
3045 MINUTES CONTROL 
SLEEP DEPRIVATION 
70.U19.8 
193.H42.2* 
45-60 MINUTES CONTROL 
SLEEP DEPRIVATION 
51.1119.0 
195.U423* 
TOTAL COUNTS CONTROL 
SLEEP DEPRIVATION 
366.9164.3 
1029.31171.4** 
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Figure 1. The effect of sleep deprivation on the locomotor activity 
Control — sleep 
deprivation 
*-p<0.05 
**-p<0.0 1 
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Tabic 2. The effect of diazepam on the changes in the locomotor 
activity of mice caused by sleep deprivation (SD). The data are mean 
values ± SEM of groups from 7-8 animals. *-P<0.05, **-140.01 
Dose Group Counts/60 min % of inhibition 
mg/kg) 
0.25 CONTROL/SALINE 492.1*82.3 
CONTROI/DIAZEPAM 313.6±78.8 -572% 
SD/SALINE 511.61119.7 
SD/DIAZEPAM 419.6±146.8 -22.0% 
0.5 CONTROL/SALINE 549.2±69.0 
CONTROL/DIAZEPAM 331.9±56.9* -65.9% 
SD/SALINE 788.6±111.9 
SD/DIAZEPAM 143.4±64.1** -81.8% 
1200 -
960 -
tri 
§ 720 
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о 
п 
о 480 
240 
0 
*-р<0.05 
*-*-рсО.ООО1 
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SD+DIAZ 
Figure 2. The effect of diazepam on the locomotor activity of mice 
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Table 3. The effect of flumazenil on the changes in the locomotor 
activity of mice caused by sleep deprivation (SD). 
The data are mean values ± SEM of groups from 10 animals. 
* - 140.005, ** - P<0.001 
DOSE GROUP COUNTS % OF INHIBITION 
MG/KG 
5 CONTROL/SALINE 385.3±16.7 
CONTROL/FLUMAZENIL 310.9±9.1 -19.3% 
SD/SALINE 932.0±49.1 
SD/FLUMAZENIL 273.4H6.7** -70.6% 
10 CONTROL/SALINE 574.9±22.1 
CONTROl/FLUMAZENIL 369.0H7.5** -35.8% 
SD/SALINE 851.5135.6 
SD/FLUMAZENIL 405.6134.6** -52.3% 
Table 4. The effect of RO 154513 in the dose lmj/kg on the changes 
in the locomotor activity of mice caused by sleep deprivation (SD). The 
data are mean values 1 SEM of groups from 12 animals. *P<0.0001 
GROUP Counts/60 min % OF INHIBITION 
CONTROL/SALINE 425.81332 
CONTROL/RO 15-4513 1 MG/KG 55.916.3 •7.0% 
SD/SALINE 
SD/RO 154513 1 MG/KG 
1031.3133.1 
551.9126.5* 46.4% 
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Table 5. The effect of Buspirone on the changes in the locomotor 
activity of mice caused by sleep deprivation ( SD ). The data are mean 
values ± SEM of groups from 7-8 animals.' *P<0.05, **P<0.001 
DOSE GROUP 
MG/KG 
Courits/60 min % OF INHIBITION 
2 CONTROL/SALINE 
CONTROL/BUSP1RONE 
391.6±53.9 
357.3187.8 -8.6% 
SD/SALINE 
SD/BUSP1RONE 
534.6±72.8 
140.8119.0** -73.6% 
4 CONTROL/SALINE 
CONTROL/BUSPIRONE 
530.6151.3 
353.4174.0 -33.3 
SD/SALINE 
SD/BUSPIRONE 
753.6H45.1 
159.5165.6* -78.8% 
8 CONTROL/SALINE 
CONTROL/BUSPIRONE 
431.8H45.7 
2192194.7 49.1% 
SD/SALINE 
SD/BUSPIRONE 
60221219.5 
66.7125.9* -88.911% 
Tabic 6. The effect of baclofen in the dose Img/kg on the changes in 
the locomotor activity of mice caused by sleep deprivation ( SD ). 
Locomotor activity was measured in actometer during 60 minutes. In 
this table the total number of counts during 60 minutes is shown. The 
data arc mean values ± SEM of groups from 7-8 animals. 
*-P<0.05 
GROUP COUNTS % OF INHffimON 
CONTROL/SALINE 
CONTROL/BACLOFEN lmg/kg 
404.6184.1 
293.3192.1 -27.4 
SD/SALINE 
SD/BACLOFEN lmg/kg 
946.61388.9 
167.6148.835 -82.3 
77 
Discussion 
The results of this study indicate that sleep deprivation ( SD ) causes 
an increase in the locomotor activity of mice. 
In our experiments, BDZ receptor agonist diazepam, BDZ receptor 
antagonist flumazenil ( RO 15-1788 ) and BDZ receptor partial inverse 
agonist RO 15-4513 despite of their different action on the locomotor 
activity in control mice had uniform inhibitory effect on the locomotor 
activity of SD mice. A substantial number of studies have shown that 
behavioural effects of these drugs are mediated via central benzodiazepine 
receptors ( FRATTA et al 1987 and 1990 ). 
In animal studies, BDZ receptor agonists and BDZ receptor inverse 
agonists produce opposite effects on the several behaviours. Although, 
benzodiazepine receptor antagonist flumazenil given alone does not 
produce significant behavioural changes in naive animals, it is capable of 
antagonizing the behavioural effects of both: BDZ receptor agonists and 
BDZ receptor inverse agonists. 
An uniform inhibitory action of these drugs on locomotor activity 
in SD mice evenin the doses which do not affect locomotor activity in 
control mice show that benzodiazepine receptor became sypersensitive to 
these drugs. However an increase in sensitivity of BDZ receptor itself 
cannot explain observed inhibitory effect of drugs with opposite mecha­
nism of action. It is not excluded that benzodiazepine receptor might exist 
in several interconvertible states e.g. agonist-state, inverse agonist-state or 
antagonist-state. Such a possibility has been discussed in many radioligand 
binding studies. In normal conditions there is a functional equilibrium 
between several states of BDZ receptor. Stress factors, like SD, induce 
conversion of BDZ receptor into one particular state, for example, agonist-
state. Under these conditions inverse agonist and antagonist at BDZ 
receptor receptor might act as agonists and exhibit uniform sedative action 
on the behaviour. 
The results of our experiments support the data expressed in the 
literature ( Sallanon et al 1983, Santos and Carlini 1983 ) that SD causes 
the sensitisation of animals to the action of serotoninergic drugs. The 
inhibitory effect of buspirone (acting at the 5-HT receptors ) was more 
pronounced in SD group. The cause of an increased response to 
serotoninergic drugs seen in SD animals is probably due to the increased 
sensitivity of postsynaptic serotonin receptors. 
Experiments with GABAB receptor agonist baclofen showed that the 
altered function of GABAB receptors may also have a role in excitement 
following SD. 
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Abstract 
In long-lasting experiments on albino mice spontaneous resistence to 
hypoxic-hypoxia, levomepromazinc (5 mg/kg) and haloperidole (0.5 mg/kg) 
induced antihypoxic effect were studied. The motorical activity on one 
hand and resistance to hypoxia and animals body temperature on the 
other vary during the year partly in opposite stages. The influence of 
neuroleptic drugs on these parameters has also seasonal variations. Impor­
tant role is played by the monoaminergic systems that are the main 
mechanisms of adaptation to any influence that of drugs as well. 
Introduction 
Extremal factors' influence on organism finally damages the O2-
regime and metabolism in tissues. In the pathogenesis of nervous disorders 
a hypoxic component plays important role [4]. Derivatives of gamma-
oxybutyric and gamma-aminobutyric acids are known as antihypoxic 
preparations. Neuroleptics are also used as antihypoxicants. One group of 
the butyrophenon neuroleptics (haloperidol etc.) are the derivatives of 
aminobutyric acid as well [11]. The phenothiazin derivatives 
(levomepromazine) raise anabolic processes and cause so-called "economical 
state of organism" [9]. 
At the present time the rhythms of organism's biological reactivity 
to the physical and chemical factors, pharmacological- and toxicological 
actions included, are well-known [1,2,3,5,7]. This is notable in the 
biopcriodical changes of the organism's tolerance, the receptors' sensibility 
to drugs and in the pharmacokinetics of substances [6]. 
If the experiments are carried out always at the same daytime one can 
see seasonal changes of tolerance to chemical compounds. There are 
known seasonal variations of antihypoxic effect of several drugs [7,8,9]. A 
clear periodicity emerges in the activity of neuroleptics during the 24 
hours. The sedative effect of haloperidol is more notable during darkness, 
while the animals' motor activity is higher. The reverse of the light regime 
(12 hours darkness in the daytime) caused the reverse of the effect of the 
neuroleptic drugs. Haloperidol has the peak of catalepsy in rats during 
day-time (12.00-14.00). At night the cataleptic effect is minimal. The 
cataleptic action of neuroleptics has seasonal variation too [2,3,10]. 
The aim of the present paper is to study the seasonal variations of 
resistance variations of resistance of the mice in the states of hypoxia and 
antihypoxic effect of neuroleptics (haloperidol and levomepromazine). 
Material and methods 
Seasonal experiments were carried out with 450 albino male and 
female mice with weight 23±0.3 grams. The animals were kept under 
standard vivarium conditions in an artificial luminescence light 
(lighbdark, 12 hours: 12 hours) at temperature 20±2°C, food and water - ad 
libitum. Seasonal rhythm was studied once in two weeks during two years 
(11.30 a.m.). 
Haloperidol (0.5 mg/kg) and levomepromazin (5 mg/kg) were injected 
i.p. 60 min before the behavioral and antihypoxic tests. Hypoxic-hypoxia 
was caused by putting the mice into a hermetic chamber (80 cm2) without 
CC>2 absorption. The protecting effect of the neuroleptic drugs in the state 
of hypoxia was determined by the mice's increasing survival period. 
In parallel, the changes in motorical, orientation and investigation 
activity, emotional reactivity according to vocalisation threshold (in volts), 
agressiveness caused by electric pain irritation and changes in body tem­
perature (measured per rectum) were studied. 
Results and discussion 
The resistance of intact mice's against hypoxic hypoxia essentially 
varies during the year (Table 1). It is high in February, March and Septem­
ber, low in July and December. An average mouse survives hypoxia in a 
80 cm2 hermetic chamber for 564±25 seconds. In December the survival 
period shortens for 2.5 minutes, in March it becomes longer for 1.5 
minutes. During these months a remarkable negative correlation of resis­
tance against hypoxia and motorical activity of mice appears. 
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Tabic 1. Annual variation of'resistance of intact mice to hypoxic-hypox­
ia and antihypoxic effect of levomepromazine (5 mg/kg) and haloperi­
dol (0.5 m&Zkg) 60 minutes after administration. The mean data (M±m) 
to groups of 10-15 animals. 
Months Duration of life (sec) 
Intact mice After administration of 
Levomepromazine Haloperidol 
I 588 ± 30 1124 ± 113 691 ± 18 
И 
649 ± 30 1624 ± 82 711 ± 37 
III 670 ±23 1870 ± 136+ 734 ± 45 
IV 527 ±22 1345 ± 206 770 ± 59 
V 644 ±42 2218 ± 381 656 ± 43 
VI 454 ± 24" 974 ± 93 671 ± 47 
VII 457 ± 30" 1266 ± 202 659 ± 75 
VIII 541 ± 11 769 ± 135 520 ± 52 
DC 645 ± 26" 1681 ± 149 750 ± 66+ 
X 618 ± 30 2033 ± 304* 645 ±43 
XI 573 ± 19 1272 ± 221 685 ± 47 
XII 409 ±25" 1395 ± 297 654 ± 35 
Annual 564 ±25 1464 ± 193 671 ± 47 
mean 
In comparison with annual mean ++P 5 0.01 
+P < 0.05 
Levomepromazine (5 mg/kg) prolongs the mice's survival period in 
the hermetic chamber 2.63 times at an average. Seasonal mean survival 
period is 3.2 minutes, after administration of levomepromazine over 21 
minutes. Seasonal increase of the survival period with levomepromazine 
varies essentially. The protective effect of the drug is stronger in May and 
October. The effect is the lowest in August 
The antihypoxic effect of haloperidol (0.5 mg/kg) is less expressed in 
comparison with levomepromazine. This may depend on different doses 
and different pharmacological effect. Haloperidol, unlike 
levomepromazine, has an activating component that raises animals' muscu­
lar tone a little. But not less, the antihypoxic effect of haloperidol varies 
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during the year having peaks in April and September. The lowest 
antihypoxic action appears in August. 
Biological rhythms guarantee the endurance of organism's homeosta­
sis and adaptation in the conditions of internal and environmental 
changes. An important part is played by the adrenergic and adrenocortico­
tropic systems that are the main mechanisms of organism's adaptation to 
any influence, that of drugs as well. Adrenergic system is also connected 
with the animals' motorical activity. 
In animals' antihypoxic resistance their motorical activity plays the 
determinative role. Animals with high activity are more resistant (Figure 
2). 
On figure 1 there is given the seasonal dynamics of mice resistance 
to hypoxic-hypoxia. In most cases higher motorical activity is binded with 
low resistance against hypoxia, but this negative correlation is only partial. 
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Figure 1. Annual dynamics of the resistance of intact mice to hypoxic-
hypoxia ( •), to electrical pain stimulation (— —) and 
motor activity ( -) [%-s of annual means. 
Annuel meens: 
Resistance of intact mice to hypoxic-hypoxia 562.0±25 sec, to electrical 
pain stimulation (summarized) 52.9±3.9 volts, their motor activity 
258.6±I9 impulses. 
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Figure 2. Seasonal dynamics of the levomnepromazine (5 mg/kg) 
induced antihypoxic protective effects and hypothermia in mice 60 min 
after administration (% of annual means). 
Annuel means: 
Antihypoxic protective effect of levomepromazine in mice is +1263% of 
the resistance of intact mice to hypoxic-hypoxia and -14% of hypother­
mia. 
Comparing the mice's resistance to hypoxia with the threshold caused 
by electric pain irritation one can see parallelism. During spring and 
autumn months the mice's resistance to electric irritation as well as 
hypoxic action are higher. These data are in correlation with content and 
speed of metabolism of dopamine in mice brain [6]. 
The neuroleptic drugs' antihypoxic protective effect is to a great 
extent caused by hypothermia over the serotoninergic system blockade 
(Figure 2). 
The studied drugs, especially levomepromazine, have the serotonin 
blockading effect that leads to the increase of the amount and metabolism 
speed of serotonin. 
In June and December the resistance of intact mice to hypoxia is at 
its lowest (Table 1), while the content of serotonin in the whole brain has 
its maximum peak [9]. 
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Conclusions 
1. The intact mice's motor activity, body temperature and resistance 
to hypoxia vary during the year, partly in opposite stages. The neuroleptic 
drugs' influence on these parameters has also seasonal variations. 
2. During the year haloperidol and levomepromazine have their 
highest effect on an axis spring-autumn months. 
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